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SUMMARY 
  XIV 
Men are different, women too. A concept which has long been neglected in biomedical 
research. Except for reproductive differences women were regarded as smaller men, clinical 
guidelines did not differentiate between men and women. There are, however, further 
differences. Every cell has a sex, which might influence regulation of gene expression, 
disease phenotype and drug toxicity. In drug research it is important to understand the 
pathomechanism and clinical presentation of a disease as well as the mechanism of action of 
a drug. Information on drug safety and efficacy are collected in preclinical and clinical 
studies. Natural history of disease studies provide valuable information on the clinical 
presentation of a disease. It is important to provide this information gender stratified to be 
able to offer best care to future patients. Chronic obstructive pulmonary disease (COPD) has 
traditionally been regarded as a disease of white men but today almost as many women are 
affected by the disease as men. The burden of COPD is still projected to increase, 
particularly in women. Despite this there are few studies comparing the clinical manifestation 
and clinical course in men and women with COPD. It was the aim of this thesis to contribute 
new data to the natural history of COPD with a special focus on the effect of gender. 
The studies of this thesis were conducted with data from the General Practice Research 
Database (GPRD), a large population-based database in the United Kingdom. The GPRD 
provides anonymized medical information on a 5% representative sample of the UK 
population. This thesis presents six studies focussing on a population of 35,772 COPD 
patients, aged 40-79 years, who received their incident COPD diagnosis between 1995 and 
2005 and the same number of randomly matched COPD-free patients for comparison. In a 
case-control analysis we compared the prevalence of co-morbidities and respiratory drug 
utilization in men and women with COPD. In nested case control analyses COPD and 
COPD-free patients were compared with respect to their risk to develop cardiovascular or 
gastrointestinal outcomes, depression or cancer.  
The first study described the COPD population with respect to co-morbidities, drug use and 
survival. Patients with COPD had more co-morbidities and a lower survival than COPD-free 
patients. In COPD patients the prevalence of diabetes, myocardial infarction, stroke / 
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transient ischemic attack (TIA), arrhythmia and peptic ulcer were higher in men than in 
women while depression and osteoporosis were more prevalent in women. We observed 
small but significant gender differences in drug utilization and survival. The second study 
analysed in more detail the association between COPD and the prevalence of diabetes. The 
prevalence of diabetes was lower in the COPD group than in the COPD-free comparison 
group. This association was significant in men but not women and mainly seen in users of 
sulfonylurea. Studies 3-6 were follow-up and nested case control analyses evaluating the risk 
of the cardiovascular outcomes (arrhythmia, pulmonary embolism, deep vein thrombosis, 
myocardial infarction and stroke / TIA), gastro-oesophageal reflux disease, peptic ulcer, 
depression and cancer risk in the population of COPD patients and compared it to a COPD-
free population. The incidence of most cardiovascular diseases was higher in patients with 
COPD. COPD had a stronger impact on the risk of MI and stroke / TIA in women than in 
men. Relative risks of PE, DVT and arrhythmia were similar in men and women. Severe 
COPD materially increased the risk of MI and PE in both men and women. The incidence 
rates of GORD were slightly higher in men than in women while peptic ulcer incidence rates 
were higher in men. COPD did not materially alter the risk of GORD or peptic ulcer. Current 
use of long-acting beta agonists was associated with a decreased risk of peptic ulcer. 
Patients with COPD had a higher risk of cancer than COPD-free patients. The increased risk 
was mainly driven by a high lung cancer risk among COPD patients, which was higher in 
women than in men. This effect was seen independent of smoking status. Many patients with 
COPD developed depression during follow-up, particularly patients with severe COPD. The 
risk of depression was higher in women than in men but COPD seemed to have a greater 
impact in men than in women.  
The studies of this thesis provide further evidence that patients with COPD are at an 
increased risk of depression, most cardiovascular diseases and lung cancer. They also 
demonstrate that gender-stratified analyses are important to adequately address the risk for 
a disease. 
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1.1  GENDER IN DRUG SAFETY 
 
Personalized medicine is nowadays an often used buzzword in healthcare. Personalized 
medicine can identify fast and slow drug metabolizers thus allowing to identify patients at 
high risk for adverse drug reactions or patients benefiting from targeted anti-tumour therapy 
and thus spare those from nasty adverse reactions who will not respond.(1) Seeing all this 
progress in medicine it is astonishing that the largest genetic difference - easily 
phaenotypical differentiable - has been neglected for decades in the analysis of the safety 
profile of new drugs. Sex. 
 
1.1.1 WOMEN IN CLINICAL TRIALS – SHORT HISTORICAL OVERVIEW 
Following the thalidomide scandal in the late 1950s and early 1960s,(2) women have almost 
completely been excluded from clinical trials due to worries about teratogenic effects (and to 
avoid legal liability from prenatal exposure). A policy paper published by the American Food 
and Drug Administration (FDA) required that women with child-bearing potential were 
excluded form early clinical trials (phase I and early phase II),(3) which led to a scenario 
where women were given drugs which were never thoroughly tested on their efficacy nor 
their safety. In the 1990s therefore the ‘NIH Revitalization Act’ (1993) (4) required that 
women should be included in clinical trials after the experience of many HIV positive women 
not having access to experimental drugs at a time when almost no HIV drugs were available 
on the market and thus the potential risk to the foetus was valued higher than the risk of 
death from a life-threatening disease. An analysis of randomized controlled trials published 
between 1994 and 1999 in the New England Journal of Medicine still only found 25% women 
to be enrolled and only 14% of the trials provided gender-specific data analyses.(5) Of 46 
studies published in 2004, reporting results of clinical trials starting 1994 or later, only 13% 
reported gender-specific results.(6) Since 1999 the FDA can stop the development of a drug 
when the company tries to exclude women able to give birth from the studies of a drug 
  4 
designed for life-threatening diseases.(7) An analysis of cardiovascular clinical trials from 
1990 to 2006 found an increasing trend to report sex-specific data and a higher number of 
subgroup analyses by sex (53% in 169 studies) but raised the concern that these analyses 
are often not conducted properly.(8)   
 
1.1.2  DIFFERENT DRUG EFFECTS IN MEN AND WOMEN 
What are the clinical consequences of not appropriately testing drugs in men and women; do 
women experience more adverse events than men? An analysis of all serious adverse 
events reported to the FDA between 1998 and 2005 revealed that more women (55.5%) than 
men (45.5%) experienced adverse events.(9) Adverse events were more serious in women 
than in men. Eight out of ten drugs withdrawn from the US market between 1997 and 2000 
were withdrawn because of greater health risks for women than for men.(10) Results from an 
analysis of 48 prescription-event monitoring studies of newly marketed drugs in the UK show 
a similar picture; adult women had a 1.6 (95% CI, 1.5-1.7) increased risk of adverse events 
when compared with men.(11) Possible explanations for this observed sex-difference in 
reported adverse events include the observation that women take more drugs than men and 
thus have a greater risk to experience adverse events from drug-drug interactions, women 
are more frequently overdosed because of sex-related differences in pharmacokinetics, they 
might be more sensitive to the drug actions, they might be more likely to report adverse 
events, women become older than men and age has also been associated with increasing 
number of adverse events.(12) Age and the number of drugs taken are not sufficient to 
explain the gender difference.(13) 
Another question, more difficult to answer, is whether the drugs are really as effective in men 
and women. Different effects in men and women have, for example, been reported in the 
literature for opioids, aspirin and digoxin. Aspirin had been recommended by the American 
Heart Association to reduce the incidence of coronary heart disease in high-risk patients. A 
clinical trial conducted in women, however, reported no overall effect on the risk of 
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myocardial infarction but a decreased risk of stroke.(14) A subsequent sex-specific meta-
analysis of randomized controlled trials on aspirin and cardiovascular events showed 
different results in men and women: men profited for myocardial prevention while women did 
for stroke but not MI.(15) There is increasing evidence that opioids exert different effects in 
men and women although much more research is needed to understand the magnitude of 
this phenomena.(16) In patient controlled analgesia, men showed higher postoperative 
opioid use than women. Women were more affected by morphine-induced respiratory 
depression. Digoxin, a cardiac glycoside which had been used in the treatment of patients 
with heart failure, increased mortality in women with heart failure and depressed left 
ventricular function compared to women assigned to placebo while in men digoxin had no 
significant effect on survival.(17) 
Why do men and women react different towards drugs? Men have a Y chromosome and 
women a second X chromosome. Although this answer is by far oversimplified accumulating 
evidence shows that sex chromosomes not only encode primary and secondary sexual 
organs but are in some way involved in many other processes in the body including drug 
metabolism. “Every cell has a sex. Whether a cell contains a XX or a XY chromosome may 
have an impact on everything from regulation of gene expression in a cell line to the efficacy 
or toxicity of a pharmaceutical in a living human.“(18)  This difference may affect the 
pharmacokinetics and the pharmacodynamics of a drug but also the presentation of the 
treatable disease itself. The drug metabolism for example is affected by differences in the 
activity of P 450 cytochrome enzymes, CYP2D6 and CYP1A2 have been associated with 
gender differences.(19) The interindividual variation in the activity of CYP enzymes is, 
however, also high, so it is not easy to distinguish gender differences from individual 
differences. The angiotensin II type 2 receptor is an example for a direct genetic difference 
as its gene is located on the X chromosome. In women usually one X-chromosome is 
randomly inactivated thus it is not clear whether this difference has an important impact on 
normal physiology and drug treatment. Genes on the X chromosome or rather the incorrect 
silencing of the second X-chromosome have also been associated with the predominance of 
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women among patients with autoimmune diseases as important genes for immune function 
are located on the X-chromosome.(20) There are many more examples of gender 
differences known, but how these differences are manifested is often not clear. Gender 
differences in pharmacokinetics and pharmacodynamics have recently been reviewed by 
Franconi et al.(19) and Soldin and Mattison (12) and the book ‘Gender Medizin’ by Rieder 
and Lohff provides an overview about gender differences in human diseases.(21) 
 
1.1.3  PHARMACOVIGILANCE & NATURAL HISTORY OF DISEASE STUDIES 
To understand the safety of a drug it is also important to understand the molecular basis of 
the disease as this helps to understand the mechanism of action of a drug or to have at least 
a picture of the specific clinical presentation of the disease to be in a position to predict 
adverse events or put them into perspective. As part of the pharmacovigilance planning, the 
International Conference on Harmonisation (ICH) guideline E2E specifically requires 
companies to provide information on the epidemiology of the disease for which a drug is 
indicated. For important adverse events background incidence rates, i.e. the rate of an event 
in a population not exposed to the drug of interest, should be provided to be in a position to 
put the adverse events reported once the drug is on the market into perspective. This 
information has to be provided stratified by sex, whenever possible. Natural history of 
disease studies are listed as method to gain such information.(22) They employ 
epidemiological methods such as cohort and case-control studies to provide this information. 
More details on these study designs are provided in Excursus 1. 
While randomized controlled trials actively recruit patients and often have very stringent in- 
and exclusion criteria thus often providing information on a rather small (maximally a few 
thousand patients), selective group the purpose of natural history of disease studies is to 
provide a snap-shot of the real world. The advent of administrative database has made this 
possible with a reasonable effort. Today health insurances, pharmacies and GPs often keep 
electronic records of their clients, respectively patients and in some countries this information 
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EXCURSUS 1 EPIDEMIOLOGICAL STUDY DESIGNS (23) 
 
Cohort studies  
Cohort studies are interested in certain exposures and 
how this exposure influences the health of people 
exposed to it. The exposure can, for example, be a 
drug, a disease or even more abstract the year of 
birth. To put the effect of the exposure into perspective 
a comparison group is needed, this are people who 
have not been exposed. Ideally the two groups would 
be identical except for the presence or absence of the 
exposure. These two groups are then followed from 
the start of the exposure until they develop an 
outcome of interest or are lost to follow-up. Loss of 
follow-up can be due to death of the patient, end of the 
study, or the patient leaving the study. With statistical 
methods then incidence rates and relative risks can be 
calculated to estimate the impact of the exposure on 
the outcome. 
 
Case-control studies  
Case-control studies start at the point of an outcome 
and look back in time. The outcome is often a disease 
but could e.g. also be marital status. First patients with 
the disease of interest are identified, they are the 
cases. Then, to investigate why these people 
developed the disease and other did not, a control 
group is identified. Controls are people who do not 
have the disease of interest at the time the study is 
conducted. Ideally the presence or absence of the 
disease of interest would be the only difference 
between cases and controls. As this is often hard to 
fulfil, one tries to ensure that the groups are at least 
identical with respect to the most important known 
confounders such as age, sex and timing. This is done 
by matching cases and controls. The statistical power 
increases with the number of controls matched to each 
case. In these groups, i.e. cases and controls, the 
proportion of people exposed to potential risk factors 
prior to the outcome will then be quantified and 
compared. The measure to quantify the risk difference 
is the odds ratio. 
 
Nested case-control studies 
Nested case-control studies combine the cohort and 
case-control design. The first part is a cohort study  
 
 
while the second part is a case-control study, which is 
nested in the cohort population. In a first step people 
with a specific exposure and a comparison group with 
people free of the exposure are identified and followed 
until they develop an outcome of interest, die or are 
otherwise lost to follow-up. Thus the crude incidence 
rate of the outcome can be calculated. For calculating 
adjusted risk estimates one, however, uses the case-
control design. In this second part one identifies all 
patients who developed the outcome of interest, 
independent of whether they had been exposed or not 
and identifies a certain number of controls from the 
pool of the cohort who did not develop an outcome. 
Then again like in a normal case-control study cases 
and controls are compared with respect to certain risk 
factors, in this case the exposure from the cohort, and 
odds ratios are calculated. This design has been 
developed to reduce costs in traditional cohort studies 
but it also is more efficient in the use of computer 
resources in database research. 
 
 
 FIGURE 1 COHORT AND CASE-CONTROL DESIGNS 
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is available for research. Data from health insurances are provided in so-called claims 
databases; examples are the American PharMetrics® database covering information on 
medical and pharmacy claims from more than 55 million people and the Medicaid database, 
providing information of patients in the US with low income.(24) The General Practice 
Research Database (GPRD) in the UK is an example of a medical record database gaining 
information from GPs.(25) The Dutch PHARMO database provides information on patients 
from pharmacy databases, hospital databases, the Dutch medical register and the clinical 
laboratory register, the GP register, and the Dutch pathology register.(26) There are many 
more database available and probably much more to become available to research. These 
databases differ with respect to the number of people covered, the mean duration of follow-
up, information on lifestyle factors, hospital data, drug information and laboratory values. All 
the mentioned databases contain information on men and women so there should be no 
reason why the natural history of a disease should not be sex-stratified, except for the case 
that the disease only occurs in men or women such as prostate or ovary cancer. Even for 
diseases which predominantly occur in one sex information should be collected on both men 
and women as this difference in occurrence might help to understand the disease process 
and thus offer new targets for drug development. 
 
 
1.2  COPD – SHORT OVERVIEW 
 
1.2.1  DEFINITION AND DIAGNOSIS  
According to the ‘Global Initiative for Obstructive Lung Diseases’ (GOLD), chronic obstructive 
pulmonary disease (COPD) is a pulmonary disease with some extrapulmonary effects and its 
pulmonary component is associated with an abnormal inflammatory response of the lungs 
which is accompanied by a not fully reversible airflow limitation.(27) Most patients with this 
disease will present with chronic respiratory symptoms such as cough and dyspnoea on 
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exercise. The degree of airflow limitation can be determined by spirometry determining the 
forced vital capacity (FVC) and the forced expiratory volume in 1 second (FEV1). Based on 
these examinations patients can be classified into different severity categories, stage I to IV, 
mild to very severe COPD. All Patients have a FEV1/FVC ratio <0.70. Mild COPD (stage I) is 
in addition characterized by FEV1≥80% predicted, moderate COPD (stage II) by 50≤ 
FEV1<80% predicted, severe COPD (stage III) by 30≤ FEV1<50% predicted and very severe 
COPD (stage IV) by FEV1<30% predicted or FEV1 <50% and chronic respiratory failure.(27) 
Another classification of the disease the BODE index (Body mass index, degree of airflow 
Obstruction, level of functional Dyspnoea and Exercise capacity) takes also extrapulmonary 
effects into consideration.(28) It is a better predictor of subsequent survival than staging by 
FEV1 categories. In research a whole set of different definitions for COPD has been used as, 
for example, use of questionnaires asking for the presence of respiratory symptoms such as 
chronic cough, sputum production and dyspnoea, self-reported doctor diagnoses, or 
spirometric analysis.(29)  
 
1.2.2  COPD BURDEN 
The variety of methods used to define COPD makes it difficult to estimate the true burden of 
the disease. Prevalence estimates across studies vary enormously. Prevalence estimates for 
European countries during the 1990s range from 3.7% physician diagnosed COPD in 
Sweden to 11% for spirometry diagnosed COPD in Italy.(29) It is estimated that 1% of the 
general population has COPD and the prevalence increases strongly to 10% when 
considering only people ≥ 40 years.(30) The prevalence and burden of COPD are projected 
to increase.(31) COPD which had been the 6th leading cause of death in 1990 is estimated to 
become the 4th leading cause of death in 2030 worldwide.(32, 33) The driving forces behind 
this increase are an aging population and the tobacco epidemic; in particular the number of 
smoking women is still projected to increase.(34)  Even if the world stopped smoking today 
  10 
COPD would cause an immense burden to the health systems worldwide due to the lag-time 
between tobacco exposure and COPD development. 
 
1.2.3  RISK FACTORS 
Smoking is often called the most important risk factor for COPD and most patients with 
COPD are current smokers or have smoked for a long time but there is a significant number 
of never smokers developing COPD ranging between 25% and 45% worldwide. A recent 
review in the Lancet focused on COPD in non-smokers.(35) A large part of these never-
smokers has, however, been exposed to other types of smoke. Smoke from biomass fuel, 
(36-38) or occupational exposure to smoke, which might be passive cigarette smoking (39), 
or exposure to gases and dust in, for example, textile and chemical industry or farming (40-
42) have all been associated with COPD. Outdoor air pollution has also been discussed to 
be associated with COPD, but is unclear whether this is restricted to exacerbations in COPD 
or also contributes to the development of COPD.(43)  
Respiratory infections are another environmental factor associated with an increased risk for 
COPD; a history of early-life respiratory infections (44, 45) as well as pulmonary tuberculosis 
in adulthood (46) have been associated with COPD. In patients already having COPD, 
respiratory infections are associated with acute exacerbations.(47)  Low socioeconomic 
status (SES) is itself associated with COPD but it is unclear whether it represents a single 
risk factor or is a marker for an increased prevalence of other risk factors associated with 
COPD. (48) People with low SES have poorer nutritional status, are more likely to live in 
heavier polluted areas, are more likely to acquire respiratory infections, lung development of 
children born to mothers of low SES might be worse than of mothers with a higher SES. Age 
is also important and one of the major criteria to distinguish COPD from asthma as COPD 
usually only develops in middle aged or older people. The ‘National Institute for Health and 
Clinical Excellence’ (NICE) guidelines refer to an age >35 years in their diagnostic 
criteria.(49) 
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But except from all these environmental factors it is also the genetic setup of people as there 
are lifelong smokers who will never develop the disease. Estimates on how many smokers 
will develop COPD range from 15% to 20% up to 50%.(50) Evidence for a genetic 
component is indicated by the observed clustering of COPD in families and the fact that lung 
function impairment can be seen in both twins in monozygotic twins but not in dizygotic twins. 
COPD is a polygenic disease.(51) The best documented genetic risk factor for COPD is the 
hereditary deficiency of alpha-1 antitrypsin.(52) Other genes associated with COPD are α1-
antichymotrypsin, cytochrome P450 A1, α2-macroglobulin, microsomal epoxide 
hydrolase.(53-55) A recent meta analysis of 12 genes of the inflammatory, 
proteinase/antiproteinase or oxidative stress pathways reported that the studied genes might 
have different effects in different ethnic populations.(56) 
 
1.2.4  PATHOPHYSIOLOGY 
Exposure to one or more of the listed environmental risk factors in combination with a genetic 
susceptibility of an individual will lead to characteristic pathophysiological changes in the 
lung. Inhaled particles induce an abnormal inflammatory response in the lung which is 
characterized by an increased number of neutrophils, macrophages and CD8+ lymphocytes. 
(57-59) These cells release proinflammatory cytokines such as interleukins and tumour 
necrosis factor (TNF)-alpha and growth factors such as transforming growth factor (TGF)-
beta.(60, 61) They also release oxidants and proteases.(61) These inflammatory processes 
are associated with constant tissue repair and remodelling. Structural changes occur in the 
peripheral airways, lung parenchyma and pulmonary vessels.(62) Breakdown of elastin by 
proteases in lung parenchyma is seen in emphysema.(63) While the parenchymal 
destruction reduces the gas transfer, the chronic inflammation present in the lung and 
narrowing of the peripheral airways is mainly responsible for the reductions in FEV1.(27) 
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1.2.5  CO-MORBIDITIES 
Increased inflammatory markers have also been noticed outside the lungs (64) and systemic 
complications of COPD are increasingly recognized.(65, 66) The current GOLD definition of 
COPD states that COPD is a disease with “some significant extrapulmonary effects that may 
contribute to the severity in individual patients”.(27) Increased systemic inflammation has 
been associated with acute exacerbations.(67) 
Cachexia and skeletal muscle wasting have early been recognized as systemic complication 
in COPD and are commonly seen in severe COPD.(68, 69) Prevalences of cachexia 
reported in COPD range between 20-40%.(68) Depression or anxiety (70-73) as well as 
heart failure (74-76) are highly prevalent co-morbid diseases in patients with COPD. Other 
cardiovascular or cerebrovascular co-morbid diseases in COPD patients include arrhythmias, 
angina pectoris, hypertension, myocardial infarction, stroke or pulmonary embolism.(74, 76) 
Lung cancer is a common neoplasm in patients with COPD, mainly resulting from 
smoking.(77-79) More detailed information on potential associations between COPD and 
cancer, cardiovascular diseases, depression, diabetes, gastro-oesophageal reflux disease or 
peptic ulcer are presented in the introduction sections of the respective studies (Studies 4.2-
4.6). 
 
1.2.6  TREATMENT  (27, 49) 
Smoking cessation is so far the only management shown to have an effect on lung function 
decline and thus success in halting or at least slowing down the disease process.(80) That is 
why current guidelines promote smoking cessation as the first step of intervention for all 
COPD patients no matter what disease stage they are in. Respiratory medication is 
introduced in a step-wise process. The main purpose is to relief symptoms and to slow 
disease progression but so far none of them is able to cure the disease. Short-acting 
bronchodilators - either beta 2 agonists or anticholinergics - are the first choice. In case 
patients remain symptomatic use of long-acting bronchodilators - tiotropium or beta 2 
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agonists - are recommended. Methylxanthines, inhaled and oral corticosteroids are further 
options in COPD management. Cases with severe COPD require oxygen therapy and finally 
pulmonary rehabilitation and lung surgery might be necessary. These procedures can be 
accompanied by alpha-1 antitrypsin replacement therapy, mucolytic therapy and anti-oxidant 
therapy where appropriate. In case of exacerbations antibiotic therapy is advised.  
 
 
1.3  GENDER DIFFERENCES IN COPD 
 
In an review article published in Thorax 1999 Becklake and Kauffmann stated “in population 
based (epidemiological) studies of airway disease, gender is invariably considered a 
standardising variable rather than a determinant worthy of investigation in its own right”.(81) 
Since then a number of studies on gender in COPD have been published but a clinical 
commentary on gender and COPD in 2007 still stated “investigations targeting gender-
related differences are in their infancy”.(82) The German textbook on Gender Medicine, 
published in 2008 does not provide a chapter on pulmonology. The second edition of 
“Principles of Gender-specific Medicine” published in 2010 provides a chapter on COPD but 
still states “There have been relatively few studies comparing clinical manifestation and 
clinical course of COPD between men and women”.(83) The following paragraphs will 
provide a short summary on gender in COPD with respect to burden, risk factors, diagnosis 
and pharmacological management. 
 
1.3.1  GENDER DIFFERENCE IN COPD BURDEN AND RISK FACTORS 
COPD prevalences in women have historically been lower than in men but trends from the 
UK (84) as well as other countries such as Canada (85), the US (86) and Austria (87) 
suggest that women are catching up. In the UK COPD prevalence rates plateaued in the mid 
nineties in men while the prevalence rates in women continuously rose between 1990 and 
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1997 when the study by Soriano et al. ended, from 0.80% to 1.36%.(84) This increase of 
COPD in women is thought to arise from an increase in tobacco consumption.(88, 89) 
Cigarette smoking became the most popular form of tobacco consumption in the 20th century. 
In the UK tobacco consumption peaked at the end of the 1940s in men and in the 1960s in 
women.(90) The prevalence of smoking in women in developing countries is still projected to 
increase.(34) It is estimated that there will be about 532 million smoking women world-wide 
in 2025.(34) Thus it is likely that the number of women developing COPD due to tobacco 
exposure is still going to increase worldwide in the future. Although smoking is often reported 
the most important risk factor for COPD, there is also a significant number of non-smokers 
developing COPD, as stated above.(35) In this subgroup of COPD patients women 
outnumber men world-wide (91), mainly due to exposure to indoor air pollution derived from 
cooking (and heating) with biomass fuels such as coal and wood, which is still commonly 
seen in rural areas of developing countries. (36, 37, 92) 
It is also controversially discussed whether women are more susceptible to the detrimental 
effects of tobacco smoke or not.(93-97) Dransfield et al., studied 328 patients older than 45 
years and with ≥20 pack-years of smoking and FEV1/FVC>0.70 and found that Caucasian 
women were more susceptible to tobacco associated loss of lung function than Caucasian 
men. Caucasian men had smoked much more pack-years at the same level of lung function 
loss.(93) The Copenhagen City Heart Study and the Glostrup population study both also 
reported a greater lung function decline in women compared to men per pack-years smoked; 
7.4ml for women and 6.3 ml for men in the CCHS and 10.5ml and 8.4ml in the GPS.(98) 
Anthonisen et al., following patients from the Lung Health Study for 11 years did not find a 
gender difference in lung decline.(95) Two meta-analyses one published in 2000 the other in 
2006 came to opposite conclusions.(96, 97) Xu et al., reporting a higher adverse smoking 
effect in women than in men, speculate that some of the difference might be due to 
incomparable non-smoking reference groups with high smoking prevalences in men 
compared to women suggesting that non-smoking men are unhealthier than non-smoking 
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women, as shown by their data that male non-smokers have lower mean predicted lung 
function values than female non-smokers.(99)  
 
1.3.2  GENDER DIFFERENCES IN LUNG PHYSIOLOGY 
Gender differences in susceptibility to tobacco smoke or other factors contributing to COPD 
might also originate from normal physiological differences in respiratory systems between 
men and women.(100) Comparing men and women of the same height reveals that men 
have larger diameter airways and larger lung volumes than women.(101) This difference is 
already present at birth and might be controlled by sex hormones already before birth.(102) 
During foetal life the lung of a female foetus matures earlier than the lung of a male foetus. At 
birth girls have on average smaller and less heavy lungs than boys and also might have 
fewer respiratory bronchioles. Lung maturation continues through childhood into 
adolescence. Age related increases in FVC cease earlier in girls than in boys. In men 
increases in FVC are seen into the mid twenties.(81) Measuring tobacco exposure in pack-
years puts the lungs of women at a greater tobacco dose per lung surface area than lungs of 
height-matched men. Apart from mere anatomical differences in airway size, different 
hormonal and immunological status might contribute to physiological differences observed 
between pulmonary function in healthy men and women.(81, 100, 101) 
 
1.3.3  GENDER DIFFERENCES IN COPD DIAGNOSIS AND MANAGEMENT 
Gender does not only affect the risk of an individual to develop COPD but seems also to 
have an effect on the likelihood to get diagnosed and treated. Studies from Spain and 
Canada with hypothetical COPD patients suggest that COPD will be underestimated in men 
and women. The researchers provided GPs with a hypothetical COPD patient history 
randomly assigned male or female gender, all other characteristics were identical. In case of 
male gender 65% of North-American GPs assigned a COPD diagnosis compared to 49% for 
female gender, presenting spirometry results increased the likelihood of a COPD diagnosis in 
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male and female hypothetical patients. (103) Forty-two percent of the Spanish GPs assigned 
a COPD diagnosis in case of male gender compared to 31% in case of female gender, 
presenting spirometry results again increased the likelihood of a COPD diagnosis in male 
and female hypothetical patients and the gender difference disappeared.(104) The 
‘Confronting COPD International Survey’, conducted in the UK, some other European 
countries and North America, in addition reported that women were less likely to undergo 
spirometric investigation compared with men.(105) Thus women might be less likely to 
receive a COPD diagnosis than men. 
There are only few studies comparing the pharmacological management in men and women 
with COPD and the results are controversial. In a small sample of 130 spirometry-evaluated 
patients in Canada, the authors found that women were twice as likely to take respiratory 
medication for mild or moderate COPD while there was no difference in severe COPD.(106)  
Data from the EPIDEPOC study showed a difference between male and female smokers 
with COPD with respect to medication use; men received more medication than women. 
Medication use in non-smokers with COPD was more similar, here women were more likely 
to receive prescriptions for corticosteroids and short-acting beta agonist than men. (91) 
 
 
  
 
 
 
 
 
AIMS 
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The major objective of this PhD thesis was to provide further information on the natural 
history of COPD in particular to contribute to the understanding of the impact of gender and 
COPD severity on the incidence of co-morbidities using data form the GPRD. 
 
Gender-specific information on COPD is still rare when put into perspective to all the 
literature available on COPD. The objective of the first study was to learn more about the 
gender-specific clinical presentation and drug utilization of patients with COPD. Diabetes had 
been associated with COPD in cross-sectional studies and was reported to develop more 
often after a COPD diagnosis but not much was known on the prevalence of diabetes prior to 
a COPD diagnosis. The aim of the second study was therefore to investigate the association 
between incident COPD and prevalent diabetes, stratified by gender. Several studies on the 
association between COPD and co-morbidities have been reported in the literature. 
However, these studies were often cross-sectional or did not investigate incident outcomes. 
In addition studies were seldom stratified by gender. Thus the true incidence rate of many 
outcomes in men and women were lacking. The aims of the studies 3-6 were to provide 
information on the gender-stratified incidence rates of arrhythmia, cancer, deep vein 
thrombosis, depression, gastro-oesophageal reflux disease, peptic ulcer, pulmonary 
embolism, myocardial infarction, stroke/ TIA in patients with COPD and compare the risk to 
develop one of these outcomes to a population of COPD-free patients.  
 
 
  
 
 
 
 
 
METHODS 
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3.1  DATA SOURCE  
 
All studies presented in this thesis are based on data from the UK-based General Practice 
Research Database (GPRD). It is a large primary-care database established in 1987 which 
encompasses some five million patients who are enrolled with selected GPs throughout the 
UK. The General Practitioners (GPs) who contribute data to the GPRD have been trained to 
record medical information in a standard manner and to supply it anonymously. Patients are 
identifiable only via a unique identification number. Sex and year of birth are recorded for 
each patient in the database, but the exact date of birth of patients in the GPRD is not 
available for confidentiality reasons.  In the beginning the GPs used office computers 
provided by Value Added Medical Products (VAMP). In the mid-nineties, a new Windows-
based practice management software application called “Vision“ was launched, which has 
then become the dominant practice software used by GPs in the GPRD scheme. The 
recorded information includes demographics, medical diagnoses, and virtually all drug 
prescriptions. Medical diagnoses are coded by Read and ‘Oxford Medical Information 
System’ (OXMIS) codes, drug prescriptions are entered using multilex codes and contain the 
name of the preparation, route of administration, dose, and number of tablets for each 
prescription. Hospital discharge and referral letters are available for review to validate the 
diagnoses recorded in the computer record. Researchers, however, cannot directly contact 
the GP, since they do not know the name and the address of the GP.  Researchers will have 
to contact the administrators of the database (MHRA), and they will forward their request to 
the GP. Thus, anonymization is guaranteed. Patients enrolled in the GPRD are 
representative of the UK population with respect to age, sex and geographical 
distribution.(107)   
The comprehensiveness and validity of the information recorded in the GPRD has been 
evaluated several times and has proven to be of high quality.(107-112) Today the GPRD is 
managed by the Medicines and Healthcare products Regulatory Agency (MHRA), who 
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constantly supervise GP practices via defined computer algorithms and manual checks. 
Practices can be eliminated from the GPRD if data recording is of poor quality, e.g. if they 
have obvious gaps in the longitudinal data or other problems. The procedures performed by 
MHRA to guarantee data integrity and completeness of data have been recently described in 
detail.(107) To guarantee high quality of research all study protocols have to be approved by 
the Independent Scientific Advisory Committee for MHRA database research (ISAC). 
Up to March 2010 more than 750 research papers using the GPRD have been published 
including various studies focussing on COPD.(84, 113-116) Further information about the 
database can be found on the website (www.gprd.com). 
 
3.2  STUDY DESIGN 
 
3.2.1  STUDY POPULATION (studies 4.2-4.6) 
We identified in the GPRD all patients with a first-time diagnosis of COPD between January 
1, 1995 and December 31, 2005 who were aged 40 to 79 years old at the index date. We 
excluded patients with a diagnosis of COPD who had less than 3 years of active recording 
history before the COPD diagnosis. Thus, we excluded patients with prevalent or so-called 
‘historical diagnoses’, i.e. diagnoses that were recorded as part of the medical history of a 
patient and for which the diagnosis date is often not known. Cases were defined without 
regard to the subsequent occurrence of any of the outcomes of interest in this study. 
In addition, we identified at random in the GPRD one comparison subject without COPD for 
each patient with COPD, matched 1:1 on general practice, age (same year of birth), sex and 
index date (i.e. the date of the COPD diagnosis in the case group). These controls also had 
to have a history of at least 3 years in the GPRD prior to their index date (i.e. the COPD 
diagnosis date of the matched case). 
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3.2.2  FOLLOW-UP STUDY  
For the follow-up part of the study, we excluded a priori patients with a malignancy diagnosis 
(except for non-melanoma skin cancer) as well as with HIV / AIDS or with a diagnosis of 
alcoholism prior to the date of the COPD diagnosis. Within this study population, we followed 
each subject from the diagnosis of COPD (or the corresponding date in the matched 
comparison group) until their end of follow-up; the end of follow-up was defined as the date 
when the subject developed a first-time diagnosis of one of the outcomes of interest (see 
Table 3.1), left the practice, died or when the last event was recorded in the patient record 
(‘database stop date’), whatever came first. In other words, we only identified incident cases 
with an outcome of interest after the COPD diagnosis but did not search for prevalent 
diagnoses which were already present prior to the COPD diagnosis. If a subject developed 
more than one endpoint, he or she was allowed to contribute person-time to several 
outcomes, i.e. sampling of person time did not necessarily end after the first of several 
outcomes of interest had been recorded. In other words we conducted a variety of different 
person-time analyses, i.e. a separate analysis for each outcome of interest. The only 
exception to this is cancer: we first identified malignancies in COPD patients and their 
matched comparison subjects, and this diagnosis was the endpoint in a patients record in 
any case. We then identified the other outcomes in separate analyses. For these follow-up 
analyses we excluded subjects with the particular outcome of interest (as stated in Table 3.1) 
prior to the date of the COPD diagnosis, so that we included only incident cases for each 
particular outcome of interest. In addition, for certain outcomes we did not only exclude 
patients who already had the exact same diagnosis prior to the COPD diagnosis, but also 
conditions which were closely related and which are major risk factors for the outcome. For 
example, when we identified incident cases with myocardial infarction after the COPD 
diagnosis, we did not only exclude those who already had a myocardial infarction prior to 
COPD, but also patients with angina pectoris prior to the COPD diagnosis (see Table 3.1). 
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Thus, we had slightly different study populations for all the different outcomes in these 
separate follow-up studies.  
 
 
TABLE 3.1  OUTCOMES OF INTEREST AND THE EXCLUSION CRITERIA FOR THE FOLLOW-UP ANALYSIS 
 
Incident event Specific exclusion criteria 
prior to the index date 
   
Arrhythmia 
 
Pulmonary embolism (PE) 
and deep vein thrombosis 
(DVT) 
 
Myocardial infarction (MI) 
 
Cardiovascular events 
Stroke or transient ischemic 
attack (TIA) 
History of MI, stroke / TIA, 
PE, DVT, arrhythmias, 
angina pectoris 
 
  
Gastroesophageal reflux 
disease (GORD)  
 
History of GORD, Peptic 
ulcer or erosive gastritis 
Gastrointestinal events 
Peptic ulcer or erosive 
gastritis 
History of Peptic ulcer or 
erosive gastritis 
 
  
Malignancies Digestive, genitourinary, lung  
cancer and lymphoma 
History of any cancer, except 
for non-melanoma skin 
cancer 
 
  
Nervous system events Depression History of depression, 
suicide attempt 
Patients with a history of a disease listed as specific exclusion criteria prior to the index date 
were excluded. All remaining patients were then followed from the index date until they 
developed one of the incident events, died, left the practice or the study ended. 
 
 
3.2.3  NESTED CASE-CONTROL STUDIES 
We conducted nested case-control analyses to further analyze the impact of COPD and 
various potential confounders on the risk of developing an outcome of interest. For this 
purpose we identified for each case with an outcome of interest four control patients who 
were selected at random from the study population (i.e. patients with or without COPD). 
Thus, controls did not develop the outcome of interest during follow-up. These controls were 
matched to cases on age, sex, practice and index date, i.e. the date when the case had the 
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incident diagnosis of an outcome of interest. For cases and controls the same exclusion 
criteria were applied. 
 
3.3  VALIDATION OF DIAGNOSES 
 
3.3.1  COPD DIAGNOSES 
We identified COPD patients based on specific Read and OXMIS-codes recorded in the 
GPRD. Soriano et al. validated the COPD diagnoses in the GPRD by sending questionnaires 
to the GPs and showed that the diagnoses are of high quality, with a concordance of κ=0.54. 
(114) 
 
3.3.2  DIAGNOSES OF OUTCOMES OF INTEREST 
We applied a stepwise validation and analysis process for the follow-up analysis. In a first 
round we took all patients, who developed an outcome of interest, based on the clinical 
diagnosis entered in the form of a Read or OXMIS code, as this reflects the crude clinical 
picture. In a second step we then validated potential cases of interest in a two-step process: 
we first wrote a computer program to search for evidence in the computer record supporting 
the validity of the diagnosis. Then we reviewed a sample of computer profiles of cases to 
check this validation procedure. Below you find the case definitions for the outcomes of 
interest. 
Arrhythmia: All patients with a recorded arrhythmia diagnosis were identified, in total 1191 
cases.  
Pulmonary embolism: Patients must have had a PE code and had to be hospitalised within 
30 days after the diagnosis or die within 30 days after the diagnosis or start heparin or 
vitamin K antagonists or platelet aggregation inhibitors or direct thrombin inhibitors or 
fibrinolytic enzymes within 180 days after the diagnosis. Patients were not allowed to have a 
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prescription for heparin or vitamin K antagonists or platelet aggregation inhibitors or direct 
thrombin inhibitors or fibrinolytic enzymes more than 90 days before the diagnosis. 
Deep vein thrombosis: Patients must have had a DVT code and had to be hospitalised 
within 30 days after the diagnosis or die within 30 days after the diagnosis or start heparin or 
vitamin K antagonists or platelet aggregation inhibitors or direct thrombin inhibitors or 
fibrinolytic enzymes within 90 days after the diagnosis. Patients were not allowed to have 
had a prescription for heparin or vitamin K antagonists or platelet aggregation inhibitors or 
direct thrombin inhibitors or fibrinolytic enzymes more than 90 days before the diagnosis 
Myocardial infarction: Patients who were hospitalised within 30 days of the MI diagnosis, or 
who died within 30 days after the diagnosis or who started ACE antagonists or beta blockers 
or statins or vitamin K antagonists or platelet aggregation inhibitors or aspirin within 90 days 
after the diagnosis. Patients with heart surgery or who had been prescribed heparin, vitamin 
K antagonists, platelet aggregation inhibitors, direct thrombin inhibitors or fibrinolytic 
enzymes more than 30 days prior to the diagnosis date were excluded. 
Stroke / TIA: Patients with a recorded stroke / TIA and who were hospitalised within 30 days 
around the stroke diagnosis, or who died within 30 days after the diagnosis or who had a 
prescription for aspirin or heparin or vitamin K antagonists or platelet aggregation inhibitors 
or direct thrombin inhibitors or fibrinolytic enzymes within 180 days after the diagnosis. 
GORD: Patients with a recorded GORD or Barrett’s oesophagus diagnosis, who received at 
least 1 prescription for PPIs within a year around the GORD or Barrett’s oesophagus 
diagnosis and who did not have prescriptions for PPIs or H2 antagonist prior to the COPD 
index date  
Peptic Ulcer: Patients with a recorded ulcer or erosive gastritis, who received at least 1 
prescription for PPIs within a year around the ulcer or erosive gastritis diagnosis and who did 
not have prescriptions for PPIs or H2 antagonist prior to the COPD index date. 
Cancer: All patients with a recorded malignant neoplasm. 
Depression: All patients with a recorded depression were identified. For a sensitivity 
analysis we identified patients with a recorded depression, who received at least 1 
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prescription for selective serotonin reuptake inhibitors (SSRI), monoamine reuptake inhibitors 
(MNRI), monoaminooxidase A inhibitors (MAOA) or other antidepressive drugs within half a 
year around the depression diagnosis and who did not have prescriptions for the above 
mentioned drugs prior to the COPD index date.  
 
 
3.4  STATISTICAL ANALYSES 
 
Statistical analyses were performed with the statistical software SAS (release 9.1, SAS 
Institute, Inc., Cary, NC, USA). 
 
3.4.1  INCIDENCE RATES  
We estimated incidence rates and 95% confidence intervals separately for COPD and control 
patients stratified by gender and we calculated incidence rate ratios and 95% confidence 
intervals to compare incidence rates in men and women.  
 
3.4.2  CASE-CONTROL ANALYSES 
We conducted a case-control analysis to describe the COPD population with regard to co-
morbidities as well as health care and drug utilization.  
Drug utilization: For each COPD patient we assessed the exposure to respiratory 
medication and oxygen after the COPD diagnosis. We stratified drug exposure into any 
exposure after the diagnosis and exposure within 180 days after the diagnosis. To test 
whether drug exposure in women and men differed significantly we provided chi-square 
statistics.  
Survival: We compared the survival after the index date by a Kaplan Meier analysis. 
Patients who did not die during follow-up were censored either at the end of the study or 
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when they left the database. The distributions were compared using a Log likelihood ratio 
test. 
Diabetes: We used conditional logistic regression to analyze the impact of diabetes on the 
risk of COPD. We stratified the analyses by gender and adjusted the analyses for smoking 
status (none, current, past, unknown), body mass index (BMI; <18.5, 18.5-24.9, 25-29.9, 30-
60 kg/m2, or unknown), hypertension and hyperlipidemia. For each COPD patient and each 
patient of the control group we assessed the exposure to oral antidiabetics (metformin, 
sulfonylureas, thiazolidinediones and acarbose) prior to the COPD diagnosis or the 
corresponding date in the comparison group. We stratified drug exposure by duration of use 
using the following categories: unexposed, 1-2 prescriptions, 3-11 prescriptions, 12-35 
prescriptions or 36+ prescriptions.  
 
3.4.3  NESTED CASE-CONTROL ANALYSES 
We conducted nested case-control analyses to further analyze the impact of COPD and 
various potential confounders on the risk of developing an outcome of interest. We compared 
the prevalence of COPD between case patients and their controls using conditional logistic 
regression analysis. We also stratified COPD patients by COPD severity. As a surrogate 
marker for COPD severity we used COPD treatment, similar to a previous approach 
published by Soriano et al..(114) We categorized COPD patients into ‘mild’ COPD (patients 
who received no drug treatment), ‘moderate’ COPD’ (patients who received at least one 
prescription for short-acting anticholinergics, beta agonists, tiotropium, leukotriene receptor 
antagonists, inhaled steroids or xanthines, or ‘severe’ COPD (patients who needed oxygen 
treatment). We adjusted the case-control analyses for patient characteristics such as body 
mass index (BMI; <17.5, 17.5-24.9, 25-29.9, 30+ kg/m2, or unknown), smoking history (no, 
current, past, unknown), as well as for various co-morbidities and drugs associated with the 
specific outcome of interest. 
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Arrhythmia: Arrhythmia analyses were adjusted for smoking status, hypertension, use of 
beta agonists, xanthines, quinolones, macrolides, vitamin K antagonists, beta blockers, 
calcium channel blockers, diuretics, cardiac glycosides and coronary dilatators. 
PE & DVT: PE and DVT analyses were adjusted for smoking status, BMI, hypertension and 
NSAID use. 
MI: MI analyses were adjusted for smoking status, BMI, hypertension, hyperlipidemia, 
diabetes and NSAID use. For the mortality analyses we followed all patients with a diagnosis 
of myocardial infarction until they died, left the practice, or the study ended, whatever came 
first. We then did a logistic regression analysis stratified by COPD status to evaluate the 
crude impact of gender on mortality. 
Stroke / TIA analyses were adjusted for smoking status, BMI, hypertension, diabetes and 
use of aspirin. For the mortality analyses we followed all patients with a diagnosis of stroke / 
TIA until they died, left the practice, or the study ended, whatever came first. We then did a 
logistic regression analysis stratified by COPD status to evaluate the crude impact of gender 
on mortality. 
GORD: GORD analyses were adjusted for smoking status, BMI, systemic steroid use and 
NSAID use; further adjustment for COX-2 inhibitor use did not have a major impact on the 
results.  
Peptic ulcer: Peptic ulcer analyses were adjusted for smoking status, BMI, NSAID use, 
GORD and vitamin K antagonist use. We assessed respiratory drug exposure prior to the 
index date for both cases and controls. We conducted conditional logistic regression 
analyses to compare the type of exposure (long-acting beta 2 agonists, short-acting beta 2 
agonists or no exposure) and the timing of exposure (current, recent or past). Current users 
had a last prescription for a study drug recorded within 60 days, recent users between 60 
and 364 days, and past users ≥ 365 days prior to the index date. We adjusted these 
analyses for BMI, smoking status, use of NSAIDs, vitamin K antagonists, xanthines, inhaled 
steroids, inhaled short-acting anticholinergics or tiotropium and for the presence of 
diagnosed GORD prior to the index date. 
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Cancer: We provided the risk estimates stratified for different cancer sites and adjusted for 
patient characteristics such as BMI, smoking history, as well as for various cancer type 
specific confounders (breast cancer: contraceptive use, hormone replacement therapy use, 
benign neoplasms, non-melanoma skin cancer, and NSAID use; lymphoma: benign 
neoplasms, use of carcinogenic drugs; gastro-oesophageal cancer: gastro-oesophageal 
reflux disease, benign neoplasms, non-melanoma skin cancer; colorectal cancer: NSAID 
use, constipation, benign neoplasms, non-melanoma skin cancer; female reproductive 
system cancer: contraceptive use, hormone replacement therapy use, benign neoplasm, 
non-melanoma skin cancer, NSAID use; urinary system cancers: hypertension, benign 
neoplasms, use of diuretics, use of carcinogenic drugs, urinary dysfunction). We provided 
risk estimates for lung cancer stratified by smoking status and gender and adjusted for BMI. 
Depression: Depression analyses were adjusted for smoking status, BMI, serious infections, 
sleeping disorders and cardiovascular diseases (deep vein thrombosis, pulmonary embolism, 
ischemic heart disease, or stroke / TIA). In addition to analyzing all cases with an incident 
diagnosis of depression, we also conducted sensitivity analyses in which we only included 
cases with an incident depression diagnosis followed by specific pharmacological treatment, 
(see case definition). We further assessed the time between the first COPD diagnosis and 
the first depression diagnosis in two-year intervals and explored whether the risk of 
developing a depression diagnosis was dependent on the duration of COPD. We stratified 
this conditional regression analysis by gender and adjusted for smoking status, BMI, 
cardiovascular diseases (pulmonary embolism, deep vein thrombosis, ischemic heart 
disease, stroke / TIA), a history of serious infections, sleeping disorders, and for COPD 
treatment (oxygen use, beta agonist use, anticholinergic use and use of xanthines), which 
have been associated with depression in univariate analyses. Statistical significance was set 
at p < 0.05. 
In addition, we assessed among patients with COPD the proportion of cases who developed 
depression and who died within one year after the depression diagnosis. We compared this 
proportion to the proportion of COPD patients who died within a year after the index date 
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without having developed depression in order to assess the impact of depression on 
mortality among COPD-patients.    
 
 
 
  
 
 
 
 
 
RESULTS 
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4.1  GENDER, CO-MORBIDITIES AND DRUG UTILIZATION IN COPD 
 
4.1.1  ABSTRACT 
The burden of COPD is still projected to increase, particularly in women. It is controversially 
discussed whether women are more susceptible to COPD than men. Self-reported health 
status is often lower in women than in men. Not much is known about gender-specific co-
morbidity profiles and drug utilization. It was the aim of this study to learn more about gender 
differences and equalities in the clinical presentation at the first-time diagnosis of COPD and 
the use of respiratory medication in patients with COPD. We used the UK-based General 
Practice Research Database (GPRD) to assess the prevalence of various co-morbidities in 
COPD patients aged 40-79 between 1995 and 2008, and we randomly matched COPD-free 
control patients to COPD patients, matched on age, sex, general practice, calendar time and 
years of history in the database. We identified the prevalence of a range of co-morbidities 
prior to the COPD diagnosis and compared respiratory drug utilization after the index date. In 
addition we compared survival between patients with and without COPD. We identified 
47,576 patients with COPD and the same number of COPD-free patients. The percentage of 
non-smokers among COPD patients was higher in women (22.9%) than in men (17.9%) and 
women tended to be slightly younger. In COPD patients the prevalence of diabetes, 
myocardial infarction, stroke / TIA, arrhythmia and peptic ulcer were higher in men than in 
women while depression and osteoporosis were more prevalent in women. Women received 
slightly more prescriptions for beta agonist (short-acting and long-acting) and inhaled 
corticosteroids while men received more prescriptions for tiotropium and combination 
preparations. Survival in patients with COPD was significantly decreased compared to 
COPD-free patients (p<0.01). The study provides further evidence that patients with COPD 
have more co-morbidities and decreased survival when compared to COPD-free patients. 
Gender differences exist with regard to the co-morbidity distribution, drug utilization and 
survival. 
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4.1.2  INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a common disease among adults 40 years 
of age or older world-wide (104) and in contrast to other chronic diseases the burden of 
COPD is still projected to increase.(31) COPD had been the 6th leading cause of death in 
1990 and is estimated to become the 4th leading cause of death in 2030 worldwide.(32, 33) 
This is contributed to an aging population and the tobacco epidemic.(88) Prevalences in 
women have historically been lower than in men but trends from the UK (84) as well as other 
countries such as Canada (85), the US (86) and Austria (87) suggest that women are 
catching up. This increase of COPD in women is thought to arise from an increase in tobacco 
consumption.(88) It is controversially discussed whether women are more susceptible to the 
detrimental effects of tobacco smoke or not.(93-97) World-wide the proportion of women 
among non-smoking COPD patients is higher than the proportion of men.(91) 
There are only few studies analysing the co-morbidity profile or medication use in COPD 
patients stratified by gender.(91, 106, 117) Most studies focus on COPD-related symptoms 
or quality-of life.(82, 118, 119) Women with COPD report more often symptoms of 
breathlessness (106) and a lower health status, even after adjusting for smoking.(120) Using 
the Charlson co-morbidity index, in 53 FEV1-matched men and women attending a Spanish 
pulmonary clinic, however, men were reported to experience more co-morbidities. The 
authors contribute this observation to older age of men when compared with women.(117) 
Data from the EPIDEPOC study in 10,711 patients with COPD, a quarter of them women, 
report a higher number of most studied co-morbidities in male smokers with COPD when 
compared with female smokers. Men had significant more hypertension, heart disease, 
gastroduodenal ulcer and women had more depression and anxiety. They also showed a 
difference between male and female smokers with COPD with respect to medication use; 
men received more medication than women. Medication use in non-smokers with COPD was 
more similar, here women were more likely to receive prescriptions for corticosteroids and 
short-acting beta agonist than men. (91) In a Canadian study women with mild or moderate 
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COPD received more prescriptions for respiratory medication than men, while men and 
women with severe COPD had a similar drug utilization pattern. (106)  
It was the aim of the current study to learn more about the clinical presentation and 
management with respiratory medication of men and women with COPD at the time of their 
first diagnosis.  
 
4.1.3  METHODS  
For detailed information on the database and study design please refer to the general 
methods section here only the information on the study population, case validation and 
statistical analyses are repeated.  
Study population: We identified in the GPRD all patients with a first-time diagnosis of 
COPD between January 1, 1995 and autumn 2008, who were aged 40-79 years. We 
excluded patients with less than 3 years of active recording history prior to the first COPD 
diagnosis. In addition, we identified at random from the GPRD one COPD-free comparison 
subject for each COPD patient, matched 1:1 on age (same year of birth), sex, general 
practice and calendar time (i.e. on the date of the first COPD diagnosis of the COPD patient). 
We applied the same exclusion criteria to the control group as to the COPD patients. Within 
this study population we assessed and compared the prevalence of diagnosed diabetes prior 
to the COPD diagnosis or the corresponding date in the comparison group.  
Case validation: We identified patients with COPD based on recorded diagnoses. Soriano 
et al. validated the COPD diagnoses in the GPRD by sending questionnaires to the GPs and 
showed that the diagnoses are of high quality, with a concordance of κ=0.54. (114) So far at 
least 12 studies on COPD have been done using GPRD data.  
Statistical Analysis: We stratified all analyses by gender. For each COPD patient we 
assessed the exposure to respiratory medication and oxygen after the COPD diagnosis. We 
stratified drug exposure into any exposure after the diagnosis and exposure within 180 day 
after the diagnosis. To test whether drug exposure in women and men differed significantly 
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we provided chi-square statistics. We compared the survival after the index date by a Kaplan 
Meier analysis. Patients who did not die during follow-up were censored either at the end of 
the study or when they left the database. The distributions were compared using a Log 
likelihood ratio test. 
 
4.1.4  RESULTS 
We identified 47’576 patients with COPD, 23’641 of them were women. The total number of 
first-time diagnoses of COPD rose from 1127 in men and 1030 in women in 1995 to 2126 
and 2077, respectively in 2007. Time trends are similar in men and women. The crude 
incidence rate per 10,000 person years for the period 1995-2005 in men (IR 35.4, 95% CI 
34.9-35.9) was higher than in women (IR 30.2, 95% CI 29.7-30.6) across all but the youngest 
(40-49 years old) age-groups (data not shown). Characteristics of the study population at the 
time of the COPD diagnosis are displayed in Table 4.1.1 Twenty-eight percent of all women 
with a COPD diagnosis received their diagnosis below the age of 60 years compared to 24% 
of all men. The proportion of women among non-smokers with COPD was higher than the 
proportion of men (23% and 17%, respectively). Asthma, hypertension, and depression were 
common co-morbidities seen in the COPD population in both men and women. The 
prevalence of depression was almost twice as high in women as in men. Patients with COPD 
were more likely to have seen their GP in the year prior to the index date and they had a 
significantly higher mean number of GP visits in the year prior to the index date (p <0.01). 
Women had a higher number of mean GP-visits than men, both with and without COPD (p 
<0.01). The distribution of GP visits in the year prior to the index date stratified by gender and 
COPD status is displayed in Table 4.1.2.  
 
 
 
 
  41 
TABLE 4.1.1  POPULATION CHARACTERISTICS 
 Men   Women   
 COPD (%) COPD-free (%) COPD (%) COPD-free (%) 
Age (in years) 
 40-49 
 50-59 
 60-69 
 70+ 
 
1264 (5.3) 
4451 (18.6) 
8640 (36.1) 
9580 (40.0) 
 
1265 (5.3) 
4453 (18.6) 
8635 (36.1) 
9572 (40.0) 
 
1792 (7.6) 
4852 (20.5) 
7799 (33.0) 
9198 (38.9) 
 
1793 (7.6) 
4859 (20.6) 
7789 (32.9) 
9200 (38.9) 
Smoking status 
 Non-smoker 
 Smoker 
 Ex-smoker 
 Unknown 
 
4091 (17.1) 
9505 (39.7) 
8398 (35.1) 
1941 (8.1) 
 
10684 (44.6) 
4173 (17.4) 
6065 (25.3) 
3013 (12.6) 
 
5416 (22.9) 
10319 (43.7) 
6180 (26.1) 
1726 (7.3) 
 
13882 (58.7) 
3642 (15.4) 
3570 (15.1) 
2547 (10.8) 
BMI (in kg/m2) 
 <17.5 
 17.5-24.9 
 25.0-29.9 
 30.0-59.9  
 unknown 
 
303 (1.3) 
7968 (33.3) 
7348 (30.7) 
3945 (16.5) 
4371 (18.3) 
 
48 (0.2) 
6305 (26.3) 
8930 (37.3) 
3691 (15.4) 
4961 (20.7) 
 
726 (3.1) 
8740 (37.0) 
5971 (25.3) 
4800 (20.3) 
3404 (14.4) 
 
154 (0.7) 
7956 (33.7) 
6880 (29.1) 
4885 (20.7) 
3766 (15.9) 
Co-morbidities 
    
 Hypertension 6803 (28.4) 7680 (32.1) 7360 (31.1) 7931 (33.6) 
 Diabetes 1984 (8.3) 2472 (10.3) 1583 (6.7) 1634 (6.9) 
 MI 2288 (9.6) 1865 (7.8) 987 (4.2) 570 (2.4) 
 PE 340 (1.4) 233 (1.0) 412 (1.7) 215 (0.9) 
 DVT 438 (1.8) 450 (1.9) 656 (2.8) 431 (1.8) 
 Stroke / TIA 1770 (7.4) 1547 (6.5) 1331 (5.6) 1050 (4.4) 
 Arrhythmia 1992 (8.3) 1755 (7.3) 1649 (7.0) 1317 (5.6) 
 GORD 2176 (9.1) 1864 (7.8) 2565 (10.9) 2261 (9.6) 
 Ulcer 2157 (9.0) 1527 (6.4) 1360 (5.8) 819 (3.5) 
 Depression 3560 (14.9) 2728 (11.4) 7163 (30.3) 5297 (22.4) 
 Osteoporosis 455 (1.9) 198 (0.8) 1999 (8.5) 1222 (5.2) 
 Asthma 9227 (38.6) 1977 (8.3) 11194 (47.4) 2651 (11.2) 
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TABLE 4.1.2  GP-VISITS IN THE YEAR PRIOR TO THE INDEX DATE  
 Men   Women   
 COPD (%) COPD-free (%) COPD (%) COPD-free (%) 
Mean (± sd) 10.7 (± 9.4)  6.9 (± 7.8)  12.7 (± 10.2) 8.1 (± 7.9) 
Median 8 5 10 6 
No GP visit 797 (3.3) 3160 (13.2) 541 (2.3) 1921 (8.1) 
1-3 GP visits 4014 (16.8) 6651 (27.8) 2826 (12.0) 5805 (24.6) 
4-6 GP visits 4477 (18.7) 4791 (20.0) 3724 (15.8) 4837 (20.5) 
7-12 GP visits 7116 (29.7) 5349 (22.4) 6961 (29.4) 6126 (25.9) 
13-24 GP visits 5693 (23.8) 3214 (13.4) 6962 (29.5) 3995 (16.9) 
25+ GP visits 1838 (7.7) 770 (3.2) 2627 (11.1) 957 (4.1) 
sd: standard deviation 
 
 
There are small differences between men and women with regard to respiratory medication 
prescriptions. Women were more likely to receive a prescription for short-acting beta 
agonists than men, 78.4% versus 74.5% as well as long-acting beta agonists, 27.5% versus 
26.3% (p≤0.05). Women also received more prescriptions of leukotriene receptor 
antagonists: 5.2% in women compared to 3.8% in men (p≤0.05). Men were more likely to 
receive a combination of short-acting anticholinergics and beta agonists or tiotropium. Details 
on the drug utilization after the COPD diagnosis stratified by gender and age are displayed in 
Table 4.1.3. Patients with COPD were more likely to die after the index date than COPD-free 
patients (p<0.01) and men were more likely to die than women (p<0.01), in COPD and 
COPD-free patients. In total 12 328 patients with COPD died compared to 5390 without 
COPD. The survival distributions are displayed in Figure 4.1. 
TABLE 4.1.3  RESPIRATORY DRUG UTILIZATION AFTER THE COPD DIAGNOSIS 
 Men   Women   
 All  <60 years ≥ 60 years All  <60 years ≥ 60 years 
       
Short-acting anticholinergics 
Ever 7068 (28.5) 1553 (27.2) 5515 (28.9) 6896 (29.2) 1794 (27.0) 5102 (30.0) 
<180 days 3725 (15.6) 741 (13.0) 2984 (16.4) 3577 (15.1) 881 (13.3) 2696 (15.9) 
Short-acting beta agonists 
Ever 17829 (74.5) * 4282 (74.9) * 13547 (74.4) * 18528 (78.4) 5263 (79.2) 13265 (78.0) 
<180 days 12448 (52.0) * 2933 (51.3) * 9515 (52.2) * 13301 (56.3) 3729 (56.1) 9572 (56.3) 
Combination short acting anticholinergics and beta agonists 
Ever  6707 (28.0) * 1353 (23.7) 5354 (29.4) * 6222 (26.3) 1574 (23.7) 4648 (27.4) 
<180 days 3633 (15.2) * 718 (15.6) 2915 (16.0) * 3339 (14.1) 801 (12.1) 2538 (14.9) 
Tiotropium 
Ever  6938 (29.0) * 1665 (29.1) * 5273 (28.9) * 6386 (27.0) 1813 (27.3) 4573 (26.9) 
<180 days 2014 (8.4) 444 (7.8) 1570 (8.6) 1923 (8.1) 523 (7.9) 1400 (8.2) 
Long-acting beta agonists 
Ever  6303 (26.3) * 1543 (27.0) * 4760 (26.1) 6510 (27.5) 1917 (28.9) 4593 (27.0) 
<180 days 2889  (12.1) * 733 (12.8) * 2156 (11.8) * 3162 (13.4) 957 (14.4) 2205 (13.0) 
Combinations with long-acting beta agonists 
Ever  9632 (40.2) * 2579 (45.1) 7053 (38.7) 9763  (41.3) 3083 (46.4) 6680 (39.3) 
<180 days 3793 (15.8) * 1036 (18.1) * 2757 (15.1) 3995 (16.9) 1300 (56.1) 2695 (15.9) 
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TABLE 4.1.3  RESPIRATORY DRUG UTILIZATION AFTER THE COPD DIAGNOSIS 
 Men   Women   
 All  <60 years ≥ 60 years All  <60 years ≥ 60 years 
Inhaled steroids 
      
Ever  11079 (46.3) * 2628 (46.0) * 8451 (46.4) * 11781 (49.8) 3320 (50.0) 8461 (49.8) 
<180 days 8179 (34.2) * 1873 (39.5) * 6306 (40.7) * 8768 (37.1) 2405 (43.8) 6363 (44.2) 
Leukotriene receptor antagonists 
Ever  906 (3.8) * 326 (5.7) * 580 (3.2) * 1222 (5.2) 525 (7.9) 697 (4.1) 
<180 days 305 (1.3) * 105 (1.8) * 200 (1.1) * 453 (1.9) 207 (3.1) 246 (1.5) 
Theophylline 
Ever  1644 (6.9) 386 (6.8) * 1258 (6.9) 1632 (6.9) 520 (7.8) 1112 (6.5) 
<180 days 697 (2.9) 152 (2.7) * 545 (3.0) 755 (3.2) 245 (3.7) 510 (3.0) 
Oxygen 
Ever  1698 (7.1) * 212 (3.7) 1486 (8.2) 1609 (6.8) 290 (4.4) 1319 (7.8) 
<180 days 431 (1.8) 40 (0.7) * 391 (2.2) 474 (2.0) 69 (1.0) 405 (2.4) 
* The difference between men and women is significant (p-value ≤0.05) 
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  FIGURE 4.1  SURVIVAL AFTER THE INDEX DATE IN COPD AND COPD-FREE PATIENTS STRATIFIED BY GENDER 
      Based on the log likelihood ratio test the survival distributions differ significantly (p<0.01). 
 
 
4.1.5  DISCUSSION  
The prevalence of COPD has traditionally been lower in women than in men, however, 
trends from several countries have suggested that women are increasingly affected by 
COPD.(84-87) We identified almost the same number of men and women with COPD, thus 
providing further evidence for this trend. The incidence rates of COPD were, however, still 
higher in men than in women, except for the youngest age group. Women outnumber men in 
the elderly population this might explain why we observe almost the same total numbers but 
still higher incidence rates in men. The general higher life expectancy in women might also 
explain the difference in survival after the COPD diagnosis in men and women. Greater 
mortality in men compared to women had also been reported by de Torres et al..(121) Our 
results also confirm earlier reports that women tend to be younger at the time of the COPD 
diagnosis and account for a higher proportion among non-smoking COPD patients. (91, 117, 
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119) Whether non-smoking women had been exposed to environmental tobacco smoke 
could not be evaluated. 
Patients with COPD had seen their GP more often than patients who did not receive a COPD 
diagnosis in the year prior to the index date. This difference might be explained by more 
intense and frequent examinations related to the establishment of a COPD diagnosis. As 
COPD is a disease which may only be diagnosed after a patient suffers from clinical 
symptoms, and the likelihood of getting a diagnosis may increase if a patient sees the GP 
more often we might have missed COPD-diagnoses since patients with early stages of non-
symptomatic COPD might not have a diagnosis recorded. Thus, diagnostic bias may play a 
role when we included COPD patients. This sort of bias is not easy to control in observational 
studies. As there is a tendency of underreporting COPD in women (103, 104) it is important 
to stress that our results only reflect physician-diagnosed COPD, numbers of patients 
suffering from COPD might be higher. COPD diagnoses have been proven to be of high 
quality in earlier studies, thus we included all patients with a COPD diagnosis without further 
validation. (114) 
Most co-morbidities were more prevalent in COPD patients than in COPD-free patients. 
Cardiovascular diseases and peptic ulcer disease share smoking as common risk factor with 
COPD which might at least explain some of the association observed.(122, 123) People with 
depression have been reported to be less likely to quit smoking, which might be one factor 
contributing to the association between depression and COPD.(124) The prevalence of 
depression was higher in women than in men, which is not specific to COPD but also seen in 
the COPD-free comparison group. In general the lifetime prevalence of depression is 
reported to be twice as high as in men.(125, 126). The prevalence of diabetes, myocardial 
infarction, stroke/ TIA, arrhythmia and peptic ulcer were higher in men than in women with 
COPD. This confirms earlier observations from the EPIDEPOC study in Spain.(91) The fact 
that men with COPD have a lower diabetes prevalence than men without COPD is an 
interesting observation, requiring further investigations. 
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Most COPD patients received short-acting bronchodilators, followed by long-acting 
bronchodilators. This pattern of drug utilization reflects the guidelines for COPD therapy.(27, 
49) In contrast to Spanish data, patients in the UK have a higher exposure to short- and long-
acting beta agonists and inhaled steroids.(91) Gender differences in drug utilization were 
observed for beta agonists, tiotropium, inhaled corticosteroids and leukotriene receptor 
antagonists. These differences were in general small but statistically significant. Whether 
these differences were due to different needs of men and women because of different 
disease manifestations or due to different prescribing preferences of GPs when treating men 
or women cannot be evaluated with this observational study. In the EPIDEPOC study men 
were more likely to use long-acting beta agonists, anticholinergic drugs, theophyllines and 
mucolytic agents.(91) 
In summary, we provide further evidence for an increasing burden of COPD in women and 
showed that men and women present with different co-morbidities at the time of the 
diagnosis, the most prevalent being cardiovascular diseases and depression. Future 
research is needed to identify whether the observed differences in drug utilization reflect 
indeed best gender-specific care for the patients or are due a gender bias in prescribing. 
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4.2  DIABETES AND THE RISK OF COPD 
 
4.2.1  ABSTRACT 
Previous studies have reported an association between diabetes mellitus and COPD but 
most were cross-sectional or studied the incidence of diabetes in COPD populations. 
Analyses were seldom stratified by gender. We used the UK-based General Practice 
Research Database (GPRD) to assess the prevalence of diabetes mellitus in COPD patients 
aged 40-79 between 1995 and 2005, and we randomly matched COPD-free control patients 
to COPD patients, matched on age, sex, general practice, calendar time and years of history 
in the database. Conditional logistic regression analyses were used to estimate the odds 
ratio of developing a first-time COPD diagnosis in relation to pre-existing diabetes mellitus 
stratified by treatment. We identified 35,772 patients with COPD and the same number of 
COPD-free patients. The prevalence of diabetes was lower in the COPD group than in the 
control group, 7.0% and 9.6% in men, and 5.8% and 6.5% in women, respectively. Exposure 
to 36 or more prescriptions of sulfonylurea, but not to biguanides, PPARs or acarbose, was 
associated with a decreased incidence of COPD in men OR 0.69 (95% CI 0.55-0.87) but not 
in women OR 0.94 (95% CI 0.71-1.25). Diabetes is significantly underrepresented in men 
with COPD compared to men without COPD. An observation which may in part be explained 
by different smoking habits. In women there is no significant difference with regard to 
diabetes prevalence between women with and without COPD.  
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4.2.2  INTRODUCTION 
Diabetes and chronic obstructive pulmonary disease (COPD) are often coexisting in elderly 
patients as shown by many cross-sectional studies.(91, 127-129) As both - COPD and 
diabetes - are prevalent diseases among the elderly one would expect a certain co-existence 
just by chance. Most studies, if they investigated the temporal relationship between COPD 
and diabetes, focussed on the incidence of diabetes in patients with COPD and reported 
inconsistent results: some showing a positive association (130, 131) while others did not find 
an association.(132) Some studies report an association between decreased lung function 
measured by FEV1 and FCV but not the FEV1/FVC ratio (130, 133) and other studies only 
measured lung function by FEV1. (134) Stratified by GOLD categories Mannino et al. showed 
that stage 1 COPD is not associated with diabetes while stage 2, 3, 4 or 0 have been 
associated with diabetes.(130) Possible mechanisms to explain the association between 
COPD and diabetes include the presence of chronic inflammation and oxidative stress.(135) 
Only few studies focussed on a potential association between incident COPD and prevalent 
diabetes. Measuring the lung function in a community-based cohort of diabetes patients over 
a period of 7 years showed that the lung function decreased over time relative to the age, 
height and sex specific predictive values.(136) Another study from the GPRD studying 1927 
COPD patients registered in 1996 reported a protective association between diabetes and 
COPD (OR 0.57, 95% CI 0.44-0.72) when compared to COPD-free patients.(137) 
Not much is known on the effect of gender in the temporal association between COPD and 
diabetes. Comparing the proportion of patients with diabetes in men and women with COPD 
gave inconsistent results. (91, 128), (138) The risk of diabetes in COPD seems to be 
increased in both men and women but the two above mentioned studies on the association 
between incident COPD and prevalent diabetes did not report gender-specific results. 
We therefore conducted a large population-based study to evaluate the association of 
prevalent diabetes and the risk of developing a first-time diagnosis of COPD with a special 
focus on gender. 
  51 
4.2.3  METHODS 
For detailed information on the database and study design please refer to the general 
methods section here only the information on the study population, case validation and 
statistical analyses are repeated.  
Study population: We identified in the GPRD all patients with a first-time diagnosis of 
COPD between January 1, 1995 and December 31, 2005 and who were aged 40-79 years. 
We excluded patients with less than 3 years of active recording history prior to the first 
COPD diagnosis. In addition, we identified at random from the GPRD one COPD-free 
comparison subject for each COPD patient, matched 1:1 on age (same year of birth), sex, 
general practice and calendar time (i.e. on the date of the first COPD diagnosis of the COPD 
patient). We applied the same exclusion criteria to the control group as to the COPD 
patients. Within this study population we assessed and compared the prevalence of 
diagnosed diabetes prior to the COPD diagnosis or the corresponding date in the 
comparison group.  
Case validation: We identified patients with COPD based on recorded diagnoses. Soriano 
et al. validated the COPD diagnoses in the GPRD by sending questionnaires to the GPs and 
showed that the diagnoses are of high quality, with a concordance of κ=0.54.(114) Until 
March 2010, at least 11 studies on COPD have been done using GPRD data.(113) We 
identified patients with diabetes based on recorded diagnoses or administrative procedures 
used in diabetes care. We did not differentiate between diabetes typ I and typ II. To further 
ensure the validity of the diabetes diagnoses and as a surrogate marker for diabetes severity 
we stratified diabetic patients by exposure to oral antidiabetic treatment (metformin, 
sulfonylureas, thiazolidinediones and acarbose, glinides and guar gum), insulin treatment, a 
combination thereof and none thereof. 
Statistical Analysis: We stratified the analyses by gender and adjusted the analyses for 
smoking status (none, current, past, unknown), body mass index (BMI; <18.5, 18.5-24.9, 25-
29.9, 30-60 kg/m2, or unknown), hypertension and hyperlipidemia. For each COPD patient 
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and each patient of the control group we assessed the exposure to oral antidiabetics 
(metformin, sulfonylureas, thiazolidinediones and acarbose) prior to the COPD diagnosis or 
the corresponding date in the comparison group. We stratified drug exposure by duration of 
use using the following categories: unexposed, 1-2 prescriptions, 3-11 prescriptions, 12-35 
prescriptions or 36+ prescriptions.  
 
4.2.4  RESULTS 
We identified a total of 35,772 patients with a first-time COPD diagnosis between 1995 and 
2005, and the same number of matched COPD-free patients in the comparison group. The 
total study population of 71,544 patients encompassed slightly more men (51.3 %) than 
women (48.7%), and 73.3 % of the study population were 60 years of age or older at the time 
of the first recording of a COPD diagnosis. Characteristics of the study population are 
displayed in Table 4.2.1.  
The prevalence of diabetes in women was lower than in men and in patients with COPD 
lower than in patients without COPD, giving a crude odds ratio of 0.70 (95% CI, 0.65-0.76) in 
men and of 0.88 (95% CI, 0.80-0.96) in women; an observation made across all age groups 
except for the 40-49 years old, here the number of patients with diabetes was slightly higher 
in patients with a COPD diagnosis than in the COPD-free comparison group (data not 
shown). Women with COPD have a higher proportion of combined oral and insulin treatment 
(24%) than women without COPD (18%) or men with COPD (18%). In women diabetes with 
combined treatment with oral antidiabetics and insulin is associated with an increased 
number of COPD diagnoses when compared to women without diabetes (OR 1.42, 95% CI 
1.11-1.83), adjusted for BMI, smoking status, hypertension and hyperlipidemia. In men it is 
associated with a lower number of COPD diagnoses (OR 0.78, 95% CI 0.62-0.98). Details on 
the prevalence of diabetes in men and women with COPD and the comparison group 
stratified by treatment are displayed in Tables 4.2.2 and 4.2.3.  
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TABLE 4.2.1  CHARACTERISTICS OF THE STUDY POPULATION 
 COPD (%) COPD-free (%) Crude OR  (95 % CI) 
Male 18361 (51.3) 18361 (51.3) -- 
Age groups (years) 
 40-49 
 50-59 
 60-69 
 >70 
 
2432 (6.8) 
7101 (19.9) 
12075 (33.8) 
14164 (39.6) 
 
2431 (6.8) 
7105 (19.9) 
12072 (33.8) 
14164 (39.6) 
 
-- 
-- 
-- 
-- 
Smoking status 
 Non smoker 
 Current smoker 
 Ex-smoker 
 Unknown 
 
7722 (21.6) 
15472 (43.3) 
9054 (25.3) 
3524 (9.8) 
 
18030 (50.4) 
6428 (18.0) 
6431 (18.0) 
4883 (13.7) 
 
1.00 (ref) 
6.27 (5.99-6.57) 
3.65 (3.48-3.83) 
1.50 (1.41-1.60) 
BMI (kg/m2) 
 15.0-18.4 
 18.5-24.9 
 25.0-29.9 
 30.0-60.0 
 Unknown 
 
1301 (3.6) 
12026 (33.6) 
9643 (27.0) 
5660 (15.8) 
7142 (20.0) 
 
325 (0.9) 
10678 (29.9) 
11647 (32.6) 
5690 (15.9) 
7432 (20.8) 
 
3.56 (3.14-4.03) 
1.00 (ref) 
0.74 (0.71-0.76) 
0.89 (0.85-0.93) 
0.84 (0.80-0.88) 
Co-morbidities    
Hyperlipidemia 3785 (10.6) 4324 (12.1) 0.85 (0.81-0.89) 
Hypertension 9782 (27.4) 11353 (31.7) 0.80 (0.77-0.82) 
Abbreviations: BMI: body mass index, ref: reference group, CI: confidence interval; OR: 
odds ratio; ref: reference; For all diseases each disease-free status is the reference. 
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TABLE 4.2.2  PREVALENCE OF TREATED AND UNTREATED DIABETES PRIOR TO THE INDEX DATE IN MEN 
 Cases  
(%) 
Controls  
(%) 
Crude OR  
(95% CI) 
Adj.* OR  
(95% CI) 
No diabetes 17072 (93.0) 16594 (90.4) 1.00 (ref) 1.00 (ref) 
Diabetes 1289 (7.0) 1767 (9.6) 0.70 (0.65-0.76) 0.75 (0.69-0.82) 
  Untreated 
  Treated 
     Oral only 
     Insulin only 
     Combination 
347 (1.9) 
942 (5.1) 
  697 (3.8) 
  78 (0.4) 
  167 (0.9) 
461 (2.5) 
1306 (7.1) 
  969 (5.3) 
  127 (0.7) 
  210 (1.1) 
0.73 (0.63-0.84) 
0.69 (0.64-0.76) 
0.69 (0.63-0.77) 
0.58 (0.44-0.78) 
0.76 (0.62-0.94) 
0.81 (0.69-0.94) 
0.73 (066-0.81) 
0.73 (0.65-0.82) 
0.66 (0.48-0.90) 
0.78 (0.62-0.98) 
Abbreviations: ref: reference group, CI: confidence interval; OR: odds ratio; ref: reference, 
adj.* OR is adjusted for BMI, smoking status, hyperlipidemia and hypertension. 
 
 
TABLE 4.2.3  PREVALENCE OF TREATED AND UNTREATED DIABETES PRIOR TO THE INDEX DATE IN WOMEN 
 Cases  
(%) 
Controls  
(%) 
Crude OR  
(95% CI) 
Adj.* OR  
(95% CI) 
No diabetes 16407 (94.2) 16275 (93.5) 1.00 (ref) 1.00 (ref) 
Diabetes 1004 (5.8) 1136 (6.5) 0.88 (0.80-0.96) 0.96 (0.86-1.07) 
  Untreated 
  Treated 
     Oral only 
     Insulin only 
     combination 
268 (1.5) 
736 (4.2) 
  497 (2.9) 
  59 (0.3) 
  180 (1.0) 
284 (1.6) 
852 (4.9) 
  628 (3.6) 
  71 (0.4) 
  153 (0.9) 
0.93 (0.79-1.11) 
0.86 (0.77-0.95) 
0.78 (0.69-0.88) 
0.82 (0.58-1.16) 
1.17 (0.94-1.45) 
0.99 (0.81-1.21) 
0.95 (0.84-1.07) 
0.86 (0.75-0.99) 
0.79 (0.53-1.18) 
1.42 (1.11-1.83) 
Abbreviations: ref: reference group, CI: confidence interval; OR: odds ratio; ref: reference, 
adj.* OR is adjusted for BMI, smoking status, hyperlipidemia and hypertension. 
 
 
The use of oral antidiabetics stratified by type of antidiabetic, duration of use and gender is 
displayed in Tables 4.2.4 and 4.2.5. Guar gum and glinides are not listed as less than 0.1% 
of the study population have been exposed. An increased duration of use of sulfonylurea 
preparations is associated with a decreased number of COPD diagnoses in men when 
compared to unexposed men; the odds ratio of 36 or more sulfonylurea prescriptions is 0.69 
(95% CI 0.55-0.87). In women the use of sulfonylurea is not associated with a diagnosis of 
COPD. In a sensitivity analysis restricted to mutually exclusive use of sulfonylurea, 36 or 
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more prescriptions of sulfonylurea was associated with a decreased number of COPD 
diagnoses in women when compared to women not using oral antidiabetic treatment (OR 
0.52, 95% CI 0.31-0.86). 
 
 
TABLE 4.2.4  USE OF ORAL ANTIDIABETICS PRIOR TO THE INDEX DATE IN MEN 
 Cases  
(%) 
Controls  
(%) 
Crude OR  
(95% CI) 
Adj.* OR 
(95% CI) 
Sulfonylurea 
  Unexposed 
  1-2 P. 
  3-11 P. 
  12-35 P. 
  36+ P. 
 
17663 (96.2) 
54 (0.3) 
142 (0.8) 
232 (1.3) 
270 (1.5) 
 
17394 (94.7) 
52 (0.3) 
158 (0.9) 
355 (1.9) 
402 (2.2) 
 
1.00 (ref) 
1.05 (0.71-1.55) 
0.90 (0.71-1.15) 
0.66 (0.55-0.80) 
0.68 (0.55-0.83) 
 
1.00 (ref) 
1.03 (0.67-1.61) 
0.93 (0.71-1.22) 
0.65 (0.53-0.81) 
0.69 (0.55-0.87) 
Biguanides      
Unexposed 
  1-2 P. 
  3-11 P. 
  12-35 P. 
  36+ P. 
 
17735 (96.6) 
60 (0.3) 
127 (0.7) 
228 (1.2) 
211 (1.2) 
 
17544 (95.6) 
78 (0.4) 
188 (1.0) 
268 (1.5) 
283 (1.5) 
 
1.00 (ref) 
0.93 (0.65-1.32) 
0.82 (0.64-1.04) 
1.12 (0.91-1.38) 
1.07 (0.85-1.34) 
 
1.00 (ref) 
0.93 (0.63-1.38) 
0.82 (0.62-1.07) 
1.28 (1.02-1.62) 
1.09 (0.85-2.73) 
PPARs 
  Unexposed 
  1-2 P. 
  3-11 P. 
  12-35 P. 
  36+ P. 
 
18314 (99.7) 
11 (0.1) 
20 (0.1) 
12 (0.1) 
4 (0.02) 
 
18290 (99.6) 
17 (0.1) 
31 (0.2) 
21 (0.1) 
2 (0.01) 
 
1.00 (ref) 
0.72 (0.31-1.66) 
0.80 (0.45-1.43) 
0.75 (0.63-1.55) 
2.64 (0.47-14.62) 
 
1.00 (ref) 
0.56 (0.23-1.35) 
0.72 (0.38-1.36) 
0.68 (0.31-1.53) 
2.83 (0.43-18.47) 
Acarbose 
  Unexposed 
  1-2 P. 
  3-11 P. 
  12-35 P. 
  36+ P. 
 
18309 (99.7) 
16 (0.1) 
17 (0.1) 
13 (0.1) 
6 (0.03) 
 
18269 (99.5) 
16 (0.1) 
33 (0.2) 
30 (0.2) 
13 (0.1) 
 
1.00 (ref) 
1.46 (0.72-2.98) 
0.73 (0.40-.34) 
0.62 (0.32-1.22) 
0.68 (0.25-1.84) 
 
1.00 (ref) 
1.24 (0.56-2.73) 
0.63 (0.32-1.22) 
0.89 (0.43-1.85) 
0.70 (0.23-2.13) 
Adj.* OR is adjusted for BMI, smoking status, hyperlipidemia and hypertension, insulin use 
and all the variables in the table 
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TABLE 4.2.5  USE OF ORAL ANTIDIABETICS PRIOR TO THE INDEX DATE IN WOMEN 
 Cases 
(%) 
Controls  
(%) 
Crude OR 
(95% CI) 
Adj.* OR 
(95% CI) 
Sulfonylurea 
  Unexposed 
  1-2 P. 
  3-11 P. 
  12-35 P. 
  36+ P. 
 
16852 (96.8) 
36 (0.2) 
124 (0.7) 
183 (1.1) 
216 (1.2) 
 
16790 (96.4) 
48 (0.3) 
110 (0.6) 
213 (1.2) 
250 (1.4) 
 
1.00 (ref) 
0.74 (0.47-1.15) 
1.12 (0.85-1.49) 
0.84 (0.66-1.06) 
0.85 (0.66-1.08) 
 
1.00 (ref) 
0.86 (0.51-1.43) 
1.32 (0.95-1.83) 
0.91 (0.69-1.19) 
0.94 (0.71-1.25) 
Biguanides      
Unexposed 
  1-2 P. 
  3-11 P. 
  12-35 P. 
  36+ P. 
 
16894 (97.0) 
53 (0.3) 
119 (0.7) 
162 (0.9) 
183 (1.1) 
 
 16840 (96.7) 
49 (0.3) 
124 (0.7) 
171 (1.0) 
227 (1.3) 
 
1.00 (ref) 
1.07 (0.71-1.62) 
0.96 (0.72-1.27) 
0.97 (0.76-1.24) 
0.80 (0.62-1.04) 
 
1.00 (ref) 
1.15 (0.70-1.88) 
1.06 (0.76-1.47) 
0.94 (0.70-1.24) 
0.82 (0.61-1.10) 
PPARs 
  Unexposed 
  1-2 P. 
  3-11 P. 
  12-35 P. 
  36+ P. 
 
17360 (99.7) 
8 (0.1) 
21 (0.1) 
21 (0.1) 
1 (0.01) 
 
17355 (99.7) 
10 (0.1) 
20 (0.1) 
26 (0.2) 
0 (0.0) 
 
1.00 (ref) 
0.82 (0.32-2.14) 
1.10 (0.58-2.08) 
0.92 (0.50-1.67) 
-- 
 
1.00 (ref) 
0.48 (0.16-1.48) 
1.17 (0.57-2.42) 
0.95 (0.48-1.87) 
-- 
Acarbose 
  Unexposed 
  1-2 P. 
  3-11 P. 
  12-35 P. 
  36+ P. 
 
17335 (99.6) 
20 (0.1) 
26 (0.2) 
22 (0.1) 
8 (0.1) 
 
17354 (99.7) 
25 (0.1) 
14 (0.1) 
10 (0.1) 
8 (0.1) 
 
1.00 (ref) 
1.03 (0.55-1.91) 
2.07 (1.05-4.09) 
2.55 (1.18-5.52) 
1.26 (0.47-3.42) 
 
1.00 (ref) 
0.94 (0.45-1.92) 
2.82 (1.27-6.25) 
3.57 (1.49-8.52) 
1.17 (0.35-3.88) 
Adj.* OR is adjusted for BMI, smoking status, hyperlipidemia and hypertension, insulin use 
and all the variables in the table 
 
 
As smoking is the most important risk factor for COPD and might confound associations 
between diabetes and COPD we ran a sensitivity analysis stratified by smoking and the 
presence of diabetes. Comparing non-smokers with diabetes with non-smokers without 
diabetes the adjusted relative risk of COPD in men was 0.88 (95% CI 0.76-1.03) and in 
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women 1.10 (95% CI 0.94-1.28). Smokers with diabetes and ex-smokers with diabetes had 
lower odds ratios than smokers and ex-smokers without diabetes (data not shown). Testing 
for interaction showed that there is a statistically significant interaction between smoking and 
diabetes (p=0.05). 
 
4.2.5  DISCUSSION 
The prevalence of diabetes we observed is in the range reported by national statistics in the 
UK, which in men aged 45 to 74 years ranges between 6% and 16% and in women aged 45-
74 ranges between 4% and 10%.(139) Cross-sectional studies have shown that diabetes 
mellitus and COPD are often coexisting. A study using the Italian ‘Health Search Database‘ 
found a higher prevalence of diabetes mellitus in patients with COPD compared to COPD-
free patients, prevalences were 18.7% and 10.5%, respectively.(127) The prevalence of 
diabetes in US veterans with and without COPD in 1992 was both 15.1% while in 1998 the 
prevalence of diabetes in veterans with COPD was 21.1% and in veterans without COPD 
20.7%, thus there was no significant difference in diabetes prevalence between veterans with 
and without COPD.(129) We report a lower prevalence of diabetes in patients with COPD 
compared to patients without COPD. As the diabetes incidence is increased in patients with 
COPD the difference in our results compared to the results of the first study might be due to 
different timing of the analysis. There is, however, also a study measuring the lung function 
in a community-based cohort of diabetes patients over a period of 7 years, which showed 
that the lung function decreased over time.(136) This is opposite to our results. Another 
study from the GPRD studying 1927 COPD patients registered in 1996, however, also 
reported a protective association between diabetes and COPD (OR 0.57, 95% CI 0.44-0.72) 
when compared to COPD-free patients, which is even slightly lower than the odds ratios we 
found. They, however, did not stratify their analysis by gender.(137) Whether there is indeed 
a causal association between diabetes and COPD cannot be clarified by this observational 
study we simply report an interesting observation which may for example at least in part be 
confounded by differences in smoking intensity and duration, as indicated by our results in 
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non-smokers. Patients with diabetes might have a greater incentive to stop smoking than 
patients without as smoking puts diabetic patients at a higher risk of complications. Smoking 
cessation is the single most effective procedure in COPD prevention.(27) If this was the real 
explanation behind this observation it would demonstrate how potent smoking cessation - 
even of a few years – is in the prevention or at least delay of COPD development. Residual 
differences in smoking intensity and duration might also explain the difference observed 
between men and women as more women without a smoking history develop COPD and 
women usually also smoked less. We also tested whether the observed association between 
COPD and diabetes might be explained by exposure to antidiabetic drugs. We found that 
men exposed to sulfonylurea were underrepresented in patients with COPD when compared 
to patients without COPD. Whether there is really an association between sulfonylurea use 
and COPD must be clarified in other studies. We are not aware of any mechanism which 
would explain this association. It is possible that sulfonylurea are just a marker for a special 
subgroup of COPD patients.  
The results are based on GP-diagnosed COPD and diabetes. While the GPRD has been 
extensively validated in previous studies and has proven to be of high quality, including 
studies on COPD and diabetes,(114, 140) we cannot rule out the possibility that a certain 
proportion of patients with these disease diagnoses may have been missed, particularly 
those with mild forms of the disease. By matching cases and controls on practice, we 
controlled to some degree for socioeconomic status, as social deprivation shows a 
geographical pattern and therefore people from the same area are more likely to see the 
same GP. We, however, cannot exclude residual confounding by socioeconomic status or 
smoking as we only assessed smoking status but not smoking intensity. Further studies are 
necessary to determine whether there is indeed an association between COPD and diabetes 
and whether there is a real difference between men and women. 
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4.3  COPD AND THE RISK OF CARDIOVASCULAR OUTCOMES 
 
4.3.1 ABSTRACT 
Previous large epidemiological studies reporting an association between chronic obstructive 
pulmonary disease (COPD) and cardiovascular diseases, rather focussed on prevalent 
diseases than on the incidence of newly diagnosed cardiovascular outcomes. 
We used the UK-based General Practice Research Database (GPRD) to assess incidence of 
cardiovascular diseases in COPD patients aged 40-79 years between 1995 and 2005, and 
we randomly matched COPD-free comparison patients to COPD patients. In nested-case 
control analyses, we compared the risks of developing an incident diagnosis of cardiac 
arrhythmias, venous thromboembolism, myocardial infarction, or stroke between patients 
with and without COPD, stratifying the analyses by COPD-severity, using COPD-treatment 
as a proxy for disease severity.  
We identified in total 2646 cardiovascular outcomes, incidence rates of most cardiovascular 
disease were higher in men than in women. The overall relative risk estimates of developing 
an incident diagnosis of cardiac arrhythmia (OR 1.19, 95% CI 0.98-1.43), deep vein 
thrombosis (OR 1.35, 95% CI 0.97-1.89), pulmonary embolism (OR 2.51, 95% CI 1.62-3.87), 
myocardial infarction (OR 1.40, 95% CI 1.13-1.73), or stroke (OR 1.13, 95% CI 0.92-1.38), 
tended to be increased for patients with COPD as compared to COPD-free controls. Relative 
risks of arrhythmia, pulmonary embolism and deep vein thrombosis were similar in men and 
women. The relative risk estimates for myocardial infarction and stroke / TIA in women were 
increased in comparison to men. 
The findings of this large observational study provide further evidence that men and women 
with COPD are at increased risk for most cardiovascular diseases. COPD increased the risk 
of stroke / TIA in women but not in men.  
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4.3.2  INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a respiratory 
disease with an important systemic component.(27, 65) Persistent low-level systemic 
inflammation is present in COPD, reflected for example by elevated levels of C-reactive 
protein.(141) Systemic inflammation has also been associated with atherosclerosis, ischemic 
heart disease and stroke.(142) Cardiovascular events are an important cause of morbidity 
and mortality among COPD patients.(143, 144) Apart from a possible direct association 
between COPD and adverse cardiovascular outcomes, COPD therapy with beta-agonists is 
of concern (145) due to the potential of increasing the risk for cardiac arrhythmia and 
myocardial infarction. In addition, COPD patients may require treatment with macrolides and 
quinolone antibiotics (146) which themselves may also cause adverse cardiovascular effects, 
and COPD and cardiovascular diseases also share smoking as an important risk factor.(122) 
Regardless of the underlying mechanism, various studies indicate an association between 
COPD and the risk of cardiovascular diseases.(147-149) According to the ACC/AHA/ESC 
2006 guidelines for the management of patients with atrial fibrillation, supraventricular 
arrhythmias are common in patients with COPD,(150) and pulmonary embolism has 
frequently been observed during exacerbations of COPD.(151, 152) Patients with COPD who 
experienced a myocardial infarction were at a two-fold increased risk of dying within one-year 
after the myocardial infarction compared to patients without COPD,(153) and in another 
study COPD patients were at an increased risk of fatal strokes when compared to COPD-
free patients.(154) A Canadian study based on data from Saskatchewan assessed the period 
prevalence of cardiovascular events and incidence of hospitalisations and mortality from 
cardiovascular outcomes in COPD patients (155, 156) and a study based on the Kaiser 
Permanente Medical Care Program (157) provided additional information on the incidence of 
hospitalisations for cardiovascular outcomes.  
In the current study, we quantified the risks of developing an incident diagnosis of cardiac 
arrhythmia, myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism 
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(PE), stroke or transient ischemic attack (TIA) in relation to COPD using primary-care data 
from the United Kingdom (UK) between 1995 and 2005 and assessed whether there are 
gender differences. 
 
4.3.3  METHODS 
For detailed information on the database and study design please refer to the general 
methods section here only the information on the exclusion criteria, case validation and 
statistical analyses are repeated.  
Exclusion Criteria: We excluded all patients from the COPD group and from the comparison 
group who had a recorded history of congestive heart failure, MI, DVT, pulmonary embolism 
(PE), stroke, TIA, cardiac arrhythmia, prior to the first COPD diagnosis (or the corresponding 
date in the COPD-free group). 
Case definition: All patients with a recorded first-time diagnosis of cardiac arrhythmia, PE, 
DVT, MI or stroke / TIA were identified using specific disease codes recorded by the GP. We 
validated potential cases according to the pharmacological treatment recorded after the 
cardiovascular diagnosis. In order to be eligible, cases with DVT or PE had to have been 
hospitalised within 30 days after the diagnosis or had to die within 30 days after the 
diagnosis, and/or had to start treatment with heparin, vitamin K antagonists, platelet 
aggregation inhibitors, direct thrombin inhibitors or fibrinolytic enzymes within 90 (DVT) or 
180 (PE) days after the diagnosis. If potential cases had one or more prescriptions for 
heparin, vitamin K antagonists, platelet aggregation inhibitors, direct thrombin inhibitors or 
fibrinolytic enzymes recorded more than 90 days prior to the DVT diagnosis, the potential 
case was excluded from the analysis. Patients with an incident MI diagnosis had to have 
been hospitalised within 30 days of the MI diagnosis, or had to die within 30 days after the 
diagnosis, and/or they had to start a new treatment with ACE antagonists, beta blockers, 
statins, vitamin K antagonists, platelet aggregation inhibitors, or aspirin within 90 days after 
the diagnosis. Patients with heart surgery or with prescriptions for heparin, vitamin K 
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antagonists, platelet aggregation inhibitors, direct thrombin inhibitors or fibrinolytic enzymes 
more than 30 days prior to the diagnosis date were excluded. Stroke or TIA patients had to 
be hospitalised within 30 days of the stroke diagnosis, had to die within 30 days after the 
diagnosis, and/or had to have a new treatment with aspirin, heparin, vitamin K antagonists, 
platelet aggregation inhibitors, direct thrombin inhibitors or fibrinolytic enzymes within 180 
days after the diagnosis. 
Statistical Analyses: Arrhythmia analyses are adjusted for smoking status, hypertension, 
use of beta agonists, xanthines, quinolones, macrolides, vitamin K antagonists, beta 
blockers, calcium channel blockers, diuretics, cardiac glycosides and coronary dilatators. PE 
and DVT analyses are adjusted for smoking status, BMI, hypertension and NSAID use. MI 
analyses are adjusted for smoking status, BMI, hypertension, hyperlipidemia, diabetes and 
NSAID use. Stroke / TIA analyses are adjusted for smoking status, BMI, hypertension, 
diabetes and use of aspirin. 
For the mortality analyses we followed all patients with a diagnosis of myocardial infarction or 
stroke / TIA until they died, left the practice, or the study ended, whatever came first. We 
then did a logistic regression analysis stratified by COPD status to evaluate the crude impact 
of gender on mortality. 
 
4.3.4  RESULTS 
After excluding patients with prevalent cardiovascular diseases, cancer, HIV, alcoholism or 
drug abuse, we identified among the remaining study population 1191 cases with an incident 
cardiac arrhythmia diagnosis, 136 cases with an incident pulmonary embolism, 210 cases 
with an incident DVT, 511 cases with an incident MI, and 598 cases with an incident stroke / 
TIA diagnosis. In absolute terms there were more cardiovascular outcomes in men than in 
women, although women outnumbered men with regard to DVT diagnoses and in COPD 
patients also with regard to stroke diagnoses. Incidence rates of all cardiovascular endpoints 
were higher among COPD patients than among patients without COPD; the incidence rate of 
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PE was more than twice as high (12.8 / 10,000 py among COPD patients vs. 5.4 / 10,000 py 
in the comparison group). In absolute terms, the incidence rates were highest for arrhythmia 
(91.1 / 10,000 py among COPD patients and 66.7 / 10,000 py in the comparison group), and 
lowest for PE. The various incidence rates, stratified by gender, are displayed in detail in 
Table 4.3.1. Patients with COPD, both men and women, develop most cardiovascular 
outcomes slightly younger than patients without COPD an exception to this phenomena is 
the diagnosis of stroke in men. Figure 4.2 displays the age distribution at the time of the 
cardiovascular diagnosis stratified by gender for patients with and without COPD. Smoking 
prevalence was generally higher in COPD patients compared to COPD-free patients as well 
as in patients developing a cardiovascular outcome compared to patients not developing a 
cardiovascular outcome independent of COPD status. The percentage of current smokers 
was generally smaller in women compared to men. Men with COPD and MI had the highest 
current smoker percentage 51% (data not shown). 
 
 
TABLE 4.3.1  INCIDENCE RATES OF CARDIOVASCULAR DISEASES IN COPD AND CONTROL PATIENTS 
 Cases Person-time 
(years)  
IR per 10,000 py 
(95 %CI) 
IRR (95% CI) 
Arrhythmia 
 COPD-Free  
  Men 
  Women 
 COPD 
  Men 
  Women 
 
563 
288 
275 
628 
334 
294 
 
84435.2 
39532.0 
44903.3 
68958.5 
32432.2 
36526.2 
 
66.7 (61.4-72.4) 
72.9 (64.9-81.7) 
61.2 (54.4-68.9) 
91.1 (84.3-98.4) 
103.0 (92.6-114.6) 
80.5 (71.8-90.2) 
 
 
1.19 (1.01 - 1.40) 
1.00 (ref) 
 
1.28 (1.09 - 1.49) 
1.00 (ref) 
PE 
 COPD-Free  
  Men 
  Women 
 COPD 
  Men 
  Women 
 
46 
23 
23 
90 
48 
42 
 
85765.1 
40260.6 
45504.4 
70233.0 
33258.3 
36974.8 
 
5.4 (4.0-7.2)  
5.7 (3.8-8.6) 
5.1 (3.4-7.6) 
12.8 (10.4-15.8) 
14.4 (10.9-19.1) 
11.4 (8.4-15.4) 
 
 
1.13 (0.63 - 2.02) 
1.00 (ref) 
 
1.27 (0.84 - 1.92) 
1.00 (ref) 
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TABLE 4.3.1  INCIDENCE RATES OF CARDIOVASCULAR DISEASES IN COPD AND CONTROL PATIENTS 
 Cases Person-time 
(years)  
IR per 10,000 py 
(95 %CI) 
IRR (95% CI) 
DVT 
 COPD-Free  
  Men 
  Women 
 COPD 
  Men 
  Women 
 
96 
39 
57 
114 
53 
61 
 
85765.1 
40260.6 
45504.4 
70233.0 
33258.3 
36974.8 
 
11.2 (9.2-13.7) 
9.7 (7.1-13.2) 
12.5 (9.7-16.2) 
16.2 (13.5-19.5) 
15.9 (12.2-20.8) 
16.5 (12.9-21.2) 
 
 
0.77 (0.52 - 1.15) 
1.00 (ref) 
 
0.97 (0.67-1.39) 
1.00 (ref) 
MI 
 COPD-Free 
  Men 
  Women  
 COPD 
  Men 
  Women 
 
224 
147 
77 
287 
174 
113 
 
85538.9 
39990.9 
45548.0 
70055.2 
33000.8 
37054.3 
 
26.2 (23.0-29.8) 
36.8 (31.3-43.2) 
16.9 (13.5-21.1) 
41.0 (36.5-46.0) 
52.7 (45.5-61.1) 
30.5 (25.4-36.7) 
 
 
2.17 (1.67 - 2.82) 
1.00 (ref) 
 
1.73 (1.37 - 2.17) 
1.00 (ref) 
Stroke / TIA 
 COPD-Free  
  Men 
  Women 
 COPD 
  Men 
  Women 
 
298 
165 
133 
300 
134 
166 
 
84586.7 
39554.0 
45032.7 
69510.2 
32857.9 
36652.2 
 
35.2 (31.5-39.5) 
41.7 (35.8-48.6) 
29.5 (24.9-35.0) 
43.2 (38.6-48.3) 
40.8 (34.5-48.3) 
45.3 (38.9-52.7) 
 
 
1.41 (1.12 - 1.77) 
1.00 (ref) 
 
0.90 (0.72 - 1.13) 
1.00 (ref) 
Abbreviations: IR: incidence rate, CI: confidence interval; py: person years 
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FIGURE 4.2  AGE AT THE DIAGNOSIS OF THE CARDIOVASCULAR OUTCOME IN PATIENTS 
WITH AND WITHOUT COPD STRATIFIED BY GENDER 
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In order to evaluate the effect of COPD severity on the risk of developing a study outcome of 
interest, we conducted a nested case-control analysis, where we stratified COPD patients 
according to their treatment pattern into mild, moderate or severe COPD. The relative risk of 
developing arrhythmia overall was similar for patients with or without COPD (OR 1.19, 95% 
CI 0.98-1.43), and COPD severity did not alter the risk estimate substantially.  The 
arrhythmia risk was similar in men and women. The overall association between COPD and 
the risk of stroke / TIA was 1.13 (95% CI 0.92-1.38) for COPD patients as compared to 
patients without COPD, however stratification by gender revealed that there is no association 
in men (OR 0.91, 95% CI 0.69-1.21) while the association in women was 1.41 (95% CI 1.06-
1.88). This difference in men and women was only seen for mild and moderate COPD while 
men and women with severe COPD did not have an increased risk of stroke / TIA. For MI, 
the relative risk estimate was highest for patients with severe COPD (OR 3.00, 95% CI 1.53-
5.86) and tended to be slightly higher in women than in men. The relative risk of PE was 
increased across all categories of COPD severity with a particularly high risk for patients with 
severe COPD, based on only 8 cases and 6 controls (OR 7.47, 95% CI 2.35-23.7). The PE 
risk was similar in men and women. Overall, the risk of DVT was 1.35 (95% CI 0.97-1.89) for 
COPD patients compared to COPD-free controls. The risk of developing DVT was similar in 
men and women. The findings for the various cardiovascular outcomes, stratified by COPD 
severity, are displayed in Table 4.3.2. 
The total mortality of patients with myocardial infarction was higher in patients who had 
COPD (38%) than in the COPD-free patients (29%), with almost no difference between men 
and women. Most of the patients died within the first 30 days after a diagnosis of myocardial 
infarction with a slightly higher percentage of death in men than in women in this 30 days 
period: 22% of all women with COPD and myocardial infarction died within the first 30 days 
compared to 27% of all men with COPD and myocardial infarction, yielding a crude odds 
ratio of 0.77 (95% CI, 0.44-1.34), the percentages in men and women without COPD were 
19% and 17%, respectively. The overall mortality in patients with stroke and COPD was 36% 
compared to 25% in COPD-free patients with stroke. The mortality within the first 30 days 
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after a stroke diagnosis was similar in men and women with COPD, 18% and 19% 
respectively. In men and women without COPD the 30 days-mortality in women was higher 
than in men, 19% and 9%, respectively, yielding a crude odds ratio of 2.50 (95% CI 1.24-
5.02). 
 
 
TABLE 4.3.2  RISK OF CARDIOVASCULAR DISEASES STRATIFIED BY COPD SEVERITY IN MEN AND WOMEN 
 
Cases 
 
Controls 
 
Crude OR 
(95% CI) 
Adj.a OR 
(95% CI) 
Arrhythmia     
No COPD 
  Men 
  Women 
563 
288 
275 
3116 
1598 
1518 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
Any COPD 
  Men 
  Women 
628 
334 
294 
2418 
1300 
1118 
1.42 (1.25-1.61) 
1.43 (1.20-1.71) 
1.41 (1.18-1.68) 
1.19 (0.98-1.43) 
1.18 (0.90-1.55) 
1.19 (0.91-1.56) 
  Mild 
  Men 
  Women 
48 
30 
18 
191 
112 
79 
1.42 (1.01-2.00) 
1.54 (0.99-2.38) 
1.27 (0.74-2.18) 
1.64 (1.14-2.34) 
1.82 (1.15-2.89) 
1.42 (0.80-2.55) 
  Moderate 
  Men 
  Women 
548 
287 
261 
2146 
1148 
998 
1.39 (1.22-1.59) 
1.39 (1.16-1.67) 
1.40 (1.16-1.68) 
1.07 (0.86-1.32) 
1.00 (0.74-1.35) 
1.14 (0.84-1.54) 
  Severe 
  Men 
  Women 
32 
17 
15 
81 
40 
41 
2.10 (1.36-3.23) 
2.35 (1.29-4.26) 
1.86 (1.00-3.47) 
1.29 (0.79-2.11) 
1.49 (0.75-2.95) 
1.11 (0.55-2.25) 
     
PE     
No COPD 
  Men 
  Women 
46 
23 
23 
314 
157 
157 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
Any COPD 
  Men 
  Women 
90 
48 
42 
230 
127 
103 
2.57 (1.74-3.78) 
2.47 (1.44-4.24) 
2.67 (1.53-4.64) 
2.51 (1.62-3.87) 
2.58 (1.38-4.81) 
2.79 (1.44-5.42) 
  Mild 
    Men 
7 
6 
18 
14 
2.61 (1.03-6.64) 
2.81 (1.00-7.88) 
3.58 (1.32-9.70) 
3.59 (1.15-11.23) 
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TABLE 4.3.2  RISK OF CARDIOVASCULAR DISEASES STRATIFIED BY COPD SEVERITY IN MEN AND WOMEN 
 
Cases 
 
Controls 
 
Crude OR 
(95% CI) 
Adj.a OR 
(95% CI) 
    Women 1 4 1.59 (0.15-16.56) 3.63 (0.31-42.55) 
  Moderate        
    Men 
    Women 
75 
37 
38 
206 
109 
97 
2.39 (1.60-3.58) 
2.24 (1.27-3.96) 
2.55 (1.45-4.48) 
2.23 (1.42-3.50) 
2.17 (1.13-4.20) 
2.67 (1.36-5.23) 
  Severe 
    Men 
    Women 
8 
5 
3 
6 
4 
2 
8.58 (2.88-25.6) 
8.25 (2.10-32.49) 
9.08 (1.46-56.32) 
7.47 (2.35-23.7) 
8.79 (1.93-40.03) 
6.15 (0.82-45.91) 
     
DVT     
No COPD 
  Men 
  Women 
96 
39 
57 
454 
186 
268 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
Any COPD 
  Men 
  Women 
114 
53 
61 
386 
182 
204 
1.38 (1.02-1.86) 
1.36 (0.87-2.13) 
1.39 (0.93-2.08) 
1.35 (0.97-1.89) 
1.33 (0.80-2.22) 
1.36 (0.86-2.15) 
  Mild 
    Men 
    Women 
10 
5 
5 
26 
15 
11 
1.78 (0.84-3.77) 
1.55 (0.55-4.39) 
2.09 (0.70-6.26) 
1.73 (0.78-3.80) 
1.49 (0.49-4.55) 
2.19 (0.68-7.07) 
  Moderate 
    Men 
    Women 
100 
47 
53 
334 
160 
174 
1.41 (1.03-1.91) 
1.38 (0.87-2.19) 
1.42 (0.94-2.16) 
1.37 (0.97-1.94) 
1.33 (0.78-2.26) 
1.37 (0.85-2.22) 
  Severe 
    Men 
    Women 
4 
1 
3 
26 
7 
19 
0.70 (0.24-2.06) 
0.64 (0.07-5.56) 
0.72 (0.21-2.53) 
0.79 (0.26-2.39) 
0.74 (0.08-6.81) 
0.76 (0.21-2.84) 
     
MI     
No COPD 
  Men 
  Women 
224 
147 
77 
1082 
666 
416 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
Any COPD 
  Men 
  Women 
287 
174 
113 
813 
534 
279 
1.70 (1.39-2.06) 
1.47 (1.15-1.87) 
2.18 (1.57-3.03) 
1.40 (1.13-1.73) 
1.25 (0.96-1.63) 
1.77 (1.24-2.53) 
  Mild 33 64 2.43 (1.56-3.81) 1.79 (1.12-2.86) 
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TABLE 4.3.2  RISK OF CARDIOVASCULAR DISEASES STRATIFIED BY COPD SEVERITY IN MEN AND WOMEN 
 
Cases 
 
Controls 
 
Crude OR 
(95% CI) 
Adj.a OR 
(95% CI) 
    Men 
    Women 
17 
16 
49 
15 
1.52 (0.85-2.73) 
5.55 (2.63-11.71) 
1.12 (0.61-2.07) 
4.46 (2.03-9.80) 
  Moderate 
    Men 
    Women 
238 
149 
89 
726 
474 
252 
1.58 (1.29-1.94) 
1.42 (1.10-1.83) 
1.91 (1.36-2.69) 
1.30 (1.04-1.62) 
1.21 (0.92-1.60) 
1.56 (1.08-2.27) 
  Severe 
    Men 
    Women 
16 
8 
8 
23 
11 
12 
3.11 (1.62-5.95) 
2.96 (1.18-7.45) 
3.53 (1.40-8.89) 
3.00 (1.53-5.86) 
2.80 (1.06-7.38) 
3.36 (1.31-8.63) 
     
Stroke / TIA     
No COPD 
  Men 
  Women 
298 
165 
133 
1256 
614 
642 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
Any COPD 
  Men 
  Women 
300 
134 
166 
1004 
510 
494 
1.25 (1.05-1.49) 
0.98 (0.76-1.26) 
1.61 (1.25-2.08) 
1.13 (0.92-1.38) 
0.91 (0.69-1.21) 
1.41 (1.06-1.88) 
  Mild 
    Men 
    Women 
20 
10 
10 
66 
34 
32 
1.28 (0.77-2.15) 
1.13 (0.55-2.33) 
1.49 (0.72-3.10) 
1.21 (0.70-2.09) 
1.05 (0.49-2.26) 
1.47 (0.68-3.16) 
  Moderate 
    Men 
    Women 
271 
118 
153 
900 
454 
446 
1.26 (1.05-1.51) 
0.97 (0.75-1.25) 
1.64 (1.27-2.13) 
1.13 (0.92-1.38) 
0.90 (0.67-1.21) 
1.42 (1.06-1.90) 
  Severe 
    Men 
    Women 
9 
6 
3 
38 
22 
16 
0.98 (0.47-2.05) 
1.01 (0.40-2.53) 
0.89 (0.25-3.10) 
1.00 (0.47-2.15) 
0.94 (0.36-2.45) 
1.01 (0.28-3.66) 
aArrhythmia analyses are adjusted for smoking status, hypertension, beta agonist use, 
xanthine use, quinolone use, macrolide use, vitamin K antagonist use and use of beta 
blockers, calcium channel blockers, diuretics, cardiac glycosides and coronary dilatators; 
PE and DVT analyses are adjusted for smoking status, BMI, hypertension and NSAID use; 
MI analyses are adjusted for smoking status, BMI, hypertension, hyperlipidemia, diabetes 
and NSAID use; Stroke / TIA analyses are adjusted for smoking status, BMI, hypertension, 
aspirin use and diabetes. 
Abbreviations: OR: odds ratio, ref: reference value, CI: confidence interval. 
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4.3.5  DISCUSSION 
In this large observational study, we explored the association between COPD and the risk of 
developing an incident diagnosis of cardiac arrhythmia, DVT, PE, MI, or stroke / TIA. We 
quantified the prevalence of these diseases prior to the first COPD diagnosis, and we 
compared their incidence rates between COPD patients and a matched comparison group 
free of COPD. In general, the findings for the association between cardiovascular diseases 
and COPD in our study are comparable to results from studies in other health care settings 
and/or other countries. 
PE is a relatively rare outcome, but the association between COPD and PE was rather 
strong (OR 2.51, 95% CI 1.62-3.87) with incidence rates increased both in men and women 
with COPD compared to COPD-free controls. It is difficult to tell whether this association is a 
causal one or possibly the result of some diagnostic bias, since PE has been reported to be 
frequently observed during exacerbations of COPD.(151, 152) The authors of a French 
prospective cohort study investigated PE in COPD patients with unexplained exacerbations 
and reported a prevalence of PE of 25%.(151) Sidney et al. (157) reported an age-adjusted 
case patient rate per 100,000 py for hospitalized PE of 129.4 among COPD patients and a 
2.74 (95% CI 1.99-3.76)-fold increased relative risk of hospitalisation due to PE among 
COPD patients compared to control patients, adjusted for age, gender and cardiovascular 
risk morbidities. The RR in women of 2.32 (95% CI 1.58-3.41) is closely similar to the crude 
IRR 2.25 (1.38-3.66) which we found, however, their RR in men was slightly higher than in 
our analysis. A study based on Saskatchewan data reported a 5.46 (95% CI 4.25-7.02)-fold 
increased relative risk of PE for COPD patients when compared to control patients.(156) 
DVT, often preceding pulmonary embolism, was not associated with a substantially altered 
relative COPD risk when compared to the COPD-free comparison group in our study. 
In absolute terms, cardiac arrhythmia was the most frequent cardiovascular outcome 
observed in our study population. COPD patients – both men and women - were slightly 
more likely to have an incident arrhythmia diagnosis recorded than patients without COPD. 
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Part of this association might be explained by a higher exposure to arrhythmogenic drugs 
such as beta agonists, a mainstay in COPD therapy,(145) and quinolone or macrolide 
antibiotics for bacterial infections.(146) Hypoxemia and hypercapnia in COPD patients may 
also contribute to an increased risk of cardiac arrhythmias as they increase the QTc 
dispersion (QTcD).(158) The authors of a Danish study focussed on atrial fibrillation among 
COPD patients and observed an increased risk associated with reduced lung function during 
a five-year follow-up.(159) Previously reported baseline prevalences of arrhythmia in COPD 
vary; Sidney et al. (157) reported that 4.7 % of COPD patients had atrial fibrillation and 2.7% 
other arrhythmias, while a study in American Veterans found a prevalence of arrhythmias of 
14.2%.(129) A comparison of the prevalence of arrhythmias in a Canadian study found an 
OR of 1.76 (95% CI 1.64-1.89) when comparing COPD patients with COPD-free patients. 
This study did not exclude patients with a history of cardiovascular events, but the authors 
adjusted the analysis for cardiovascular co-morbidities.(156) The authors of another 
observational study stratified by COPD severity and reported relative risk estimates 
associated with various levels of COPD severity ranging from 0.92 (mild COPD) to 1.27 
(severe COPD).(154) 
We observed a rather strong association between severe COPD and the risk of developing 
an incident MI (OR 3.00, 95% CI 1.53-5.86], after adjusting for smoking, a common risk 
factor of COPD and MI. Persistent low-level systemic inflammation, reflected by increased 
levels of the C-reactive protein (CRP), is often present in patients with COPD,(141) and 
increased levels of CRP are associated with an increased MI risk. Several previous 
observational studies have reported an association between COPD and MI,(156, 157) while 
Engström et al. (160) did not detect an association between low FEV1 and cardiac events, 
defined as fatal or non-fatal MI or death from chronic ischemic heart disease. The 
association between COPD and risk of MI was higher in women than in men, an observation 
which was also reported by Sydney et al..(157) 
We found only a weak association between COPD and the risk of stroke / TIA with an OR of 
1.13 (95% CI 0.92-1.38). While the crude incidence rates in men with or without COPD were 
  72 
closely similar, COPD was associated with a 1.5-fold increased risk in women. Sidney et al. 
also reported a RR of 1.50 (95% CI 1.30-3.41) in women with COPD. (157) Truelsen et al. 
(161) explored the association between reduced lung function and the risk of stroke, resulting 
in ORs ranging between 1.00 and 1.38 for FEV1 values below 80% when compared to FEV1 
values ≥100%. Hozawa et al. (162) did not find a significant association between airway 
obstruction and ischemic stroke. Engström et al. (160) did not observe a statistically 
significantly altered risk when they studied the association between low FEV1 and stroke. 
Two other longitudinal studies found only weak associations between COPD and 
stroke.(156, 157) In COPD-free patients the 30-days mortality was greater in women than in 
men, a common observation which is often contributed to older age and more severe strokes 
in women.(163, 164) It is an interesting observation that the presence of COPD leads to 
similar rates of 30-days mortality in men and women, which needs to be further investigated 
in other studies. Whether the slightly different findings for MI and stroke / TIA incidence in 
association with COPD indeed reflect a greater vulnerability of women, or whether this is due 
to residual confounding e.g. by smoking needs further investigation. 
Several limitations of our study need to be addressed. As this study is based on data from 
the primary-care setting, there is a possibility that we might have missed some cases with 
COPD, especially patients with milder forms of COPD who have not yet been diagnosed. 
Thus, our results only apply to GP-diagnosed COPD diagnoses, and the same holds true for 
the cardiovascular outcomes. However, as most of the cardiovascular outcomes in this study 
represent acute and rather severe diseases, we can assume that few cases with an outcome 
of interest would have been missed. We decided a priori to analyze only the first 
cardiovascular event during follow-up; the various cardiovascular outcomes are highly 
related to each other and their treatment and management is similar, thus a first episode of a 
cardiovascular outcome materially alters the risk of developing a second. It would have been 
desirable to have (more) information on potential risk factors for the outcomes such as 
immobility, disease severity or socioeconomic status. We assessed COPD severity using 
medication as a proxy in the nested case-control analysis, and we stratified the analyses by 
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this parameter. However, we were not able to classify the large group of patients with 
moderate COPD (i.e. those with some pharmacological treatment) in more detail with these 
data. By matching cases and controls on practice, we controlled to some degree for 
socioeconomic status, as social deprivation shows a geographical pattern and therefore 
people from the same area are more likely to see the same GP. On the other hand, it is a 
strength of the this high-quality data source that it encompassed a large population with a 
considerably long follow-up of up to 10 years, and this database has already proven to be of 
high validity for studies of COPD and various cardiovascular outcomes. Another advantage 
of the GPRD, for example compared with other settings such as the study from the Kaiser 
Permanente Medical Care Program, is the availability of information on lifestyle factors, in 
this case particularly on smoking. Collecting information from different settings is important 
as the pattern and the impact of factors, such as smoking or the health care system, may 
vary. 
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4.4  COPD AND RISK OF REFLUX DISEASE OR PEPTIC ULCER 
 
4.4.1  ABSTRACT 
Peptic ulcer disease and gastro-oesophageal reflux disease (GORD) have been associated 
with chronic obstructive pulmonary disease (COPD). Many studies, especially on peptic ulcer 
are cross-sectional or were done back in the 1960s or 1970s. Our purpose was to learn more 
about GORD and peptic ulcer in relation to COPD during long-term follow-up in recent years. 
We conducted a case-control and a follow-up study using the UK-based General Practice 
Research Database to assess and compare the incidence of GORD and peptic ulcer in 
patients with COPD and in COPD-free patients during the period 1995-2005. We identified 
35,772 patients with COPD and the same number of COPD-free patients. Incidence rates of 
GORD and peptic ulcer in COPD patients were 59.2 and 14.8 per 10,000 person years, 
respectively. Incidence rates of GORD were higher in women while incidence rates of peptic 
ulcer were higher in men. In patients with COPD the risk of GORD was (OR 1.19, 95% CI 
1.00-1.40) and of peptic ulcer was (OR 1.24, 95% CI 0.92-1.66) compared to COPD-free 
patients. Current use of long-acting beta agonists was associated with a decreased risk of 
peptic ulcer (OR 0.38, 95% CI 0.16-0.93). The results provide further evidence that there is 
no materially increased risk for ulcer or GORD associated with COPD. The observed 
association between use of long-acting beta agonists and peptic ulcer needs further 
investigation. 
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4.4.2  INTRODUCTION 
As indicated in the recent update of the GOLD definition,(27, 65) chronic obstructive 
pulmonary disease (COPD) has increasingly been recognized to have systemic involvement 
such as depression, cardiovascular diseases or weight loss.(65)  
Gastro-oesophageal reflux disease (GORD) is a disease of considerable prevalence often 
seen in COPD patients, and it has been reported to be increasingly diagnosed in the past 
years.(165, 166) There are several hypotheses to explain the association between COPD 
and GORD, and it is important to distinguish between two temporally and thus causally 
differing approaches. According to approach one, GORD is a risk factor for developing 
COPD; GORD is thought to facilitate the development or exacerbation of COPD by irritation 
of the airways through microaspiration of gastric contents and/or by vagally mediated reflex 
bronchoconstriction.(167, 168) On the other hand, bronchial obstruction in asthma has been 
reported to affect lower oesophageal sphincter motility,(169) which may promote GORD, so 
COPD would be a risk factor for GORD.  
Another explanation for a possible association between COPD and GORD focuses on 
smoking as a common risk factor for both diseases.(170) Smoking is thought to be the most 
important common factor for COPD and gastric or duodenal ulcer, as reported in the 
past.(123, 171, 172) Only few recent studies have investigated this association despite the 
fact that both diseases have seen opposing time trends;(173, 174) the incidence of 
gastrointestinal ulcers has been decreasing, while the burden of COPD has been projected 
to increase.(31, 175) 
Proton pump inhibitors and histamine H2 receptor antagonists and Helicobacter pylori 
eradication are the mainstay of ulcer and GORD therapy.(176) Another - so far only 
experimental - strategy, targets the beta adrenergic system. In the 1980s and 1990s there 
were some reports on the role of a novel type of beta receptor, the beta 3 receptor, in the 
regulation of gastric acid secretion. In the following, selective beta-3-agonists have been 
developed against gastric ulcers and shown promising results in rats (SR 58611A, ZD 7114, 
  77 
CGP 12177A, CL 316243, BRL 37344). (177-179) Comparisons between selective beta 3 
agonists and other beta agonists and studies prior to the development of selective beta 3 
agonists, suggest that also beta 2 agonists and even the unselective agonist isoprenaline 
have protective effects against gastric ulcer.(180-182)  
It was the goal of the current observational study to assess the incidence of new onset 
GORD and gastrointestinal ulcer disease in patients with COPD compared to patients 
without COPD stratified by gender, thereby focusing on COPD severity and treatment as a 
risk factor for these outcomes. 
 
4.4.3  METHODS 
For detailed information on the database and study design please refer to the general 
methods section here only the information on the exclusion criteria, case validation and 
statistical analyses are repeated.  
Exclusion Criteria: For the analysis of GORD we excluded patients with a history of GORD, 
or gastric or duodenal ulcer; for the analysis of gastric or duodenal ulcer we excluded 
patients with a history of these ulcers prior to the COPD diagnosis date or prior to the 
corresponding date in the COPD-free group. 
Case definition: We identified all patients with a first-time recorded diagnosis of GORD, or 
peptic ulcer based on computer-recorded codes. In a computer-aided algorithm we then 
excluded all patients who had been treated with proton pump inhibitors or H2- antagonist 
prior to the COPD diagnosis to ensure that we included only incident GORD or ulcer cases. 
We also excluded patients who had no records of proton pump inhibitor use within one year 
after the GORD or ulcer diagnosis since proton pump inhibitors are recommended as a first-
line treatment for GORD and gastrointestinal ulcer disease. (176)   
Statistical Analyses: GORD analyses were adjusted for smoking status, BMI, systemic 
steroid use and NSAID use; further adjustment for COX-2 inhibitor use did not have a major 
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impact on the results. Peptic ulcer analyses were adjusted for smoking status, BMI, NSAID 
use, GORD and vitamin K antagonist use.   
We assessed drug exposure prior to the index date for both cases and controls. We 
conducted conditional logistic regression analyses to compare the type of exposure (long-
acting beta 2 agonists, short-acting beta 2 agonists or no exposure) and the timing of 
exposure (current, recent or past). Current users had a last prescription for a study drug 
recorded within 60 days, recent users between 60 and 364 days, and past users ≥ 365 days 
prior to the index date. We adjusted these analyses for body mass index (BMI) (15.0 -18.4, 
18.5-24.9, 25-29.9, 30+ kg/m2, unknown) smoking status (non, current, past, unknown), use 
of NSAIDs, vitamin K antagonists, xanthines, inhaled steroids, inhaled short-acting 
anticholinergics or tiotropium and for the presence of diagnosed GORD prior to the index 
date. 
 
4.4.4  RESULTS 
After excluding patients with prevalent GORD, ulcer, cancer, alcoholism, drug abuse or HIV, 
we identified among the remaining study population 961 patients who had a 
pharmacologically treated incident GORD-diagnosis and 247 patients who had a treated 
incident ulcer diagnosis of the stomach or duodenum. Fifty-five percent of the GORD patients 
were women and they were slightly younger at their diagnosis than men 65.7 ± 9.8 years 
compared to 67.1 ± 9.5 years. Characteristics of the GORD study population are displayed in 
Table 4.4.1. The proportion of women among patients with a peptic ulcer diagnosis was 43% 
and again women were slightly younger than men when they received their ulcer diagnosis, 
the mean ages were 69.9 ± 9.6 years and 71.8 ± 8.0 years, respectively. Women with COPD 
received their diagnosis at a younger age than women without COPD, 68.5 ± 9.5 years and 
71.4±9.6 years respectively; in men the mean age was almost similar 72.1±7.6 years and 
71.5±8.5 years, respectively. Characteristics of the peptic ulcer study population are 
displayed in Table 4.4.2.  
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TABLE 4.4.1  CHARACTERISTICS OF CASES WITH INCIDENT GORD AND THEIR CONTROLS  
 MEN  WOMEN 
 
Cases (%) 
n=433 
Controls (%) 
n=1608 
OR (95% CI)  Cases (%) 
n=528 
Controls (%) 
n=2020 
OR (95% CI) 
Mean age (years) ± sd 67.1±9.5  66.9±9.3 --  65.7±9.8 65.7±9.7 -- 
BMI (kg/m2) 
 <17.5  
 17.5-24.9 
 25.0-29.9 
 ≥30 
 unknown 
2 (0.5) 
134 (31.0) 
156 (36.0) 
69 (15.9) 
72 (16.6) 
14 (0.9) 
485 (30.2) 
555 (34.5) 
272 (16.9) 
282 (17.5) 
0.52 (0.12-2.30) 
1.00 (ref) 
1.03 (0.80-1.34) 
0.93 (0.67-1.29) 
0.92 (0.65-1.30) 
 
6 (1.1) 
195 (36.9) 
155 (29.4) 
103 (19.5) 
69 (13.1) 
42 (2.1) 
672 (33.3) 
606 (30.0) 
395 (19.6) 
305 (15.1) 
0.50 (0.21-1.20) 
1.00 (ref) 
0.88 (0.69-1.11) 
0.89 (0.68-1.18) 
0.74 (0.54-1.03) 
Smoking status 
 Non-smokers 
 Smokers 
 Ex-smokers 
 unknown 
145 (33.5) 
101(23.3) 
163 (37.6) 
24 (5.5) 
496 (30.9) 
430 (26.7) 
542 (33.7) 
140 (8.7) 
1.00 (ref) 
0.81 (0.61-1.07) 
1.07 (0.82-1.40) 
0.54 (0.32-0.90) 
 
234 (44.3) 
119 (22.5) 
146 (27.7) 
29 (5.5) 
868 (43.0) 
531 (26.3) 
468 (23.2) 
153 (7.6) 
1.00 (ref) 
0.83 (0.65-1.07) 
1.18 (0.92-1.50) 
0.61 (0.38-0.99) 
Drug exposure        
 NSAIDs 349 (80.6) 1218 (75.8) 1.33 (1.02-1.74)  439 (83.1) 1546 (76.5) 1.53 (1.19-1.98) 
 Vitamin K antagonists 29 (6.7) 125 (7.8) 0.84 (0.55-1.28)  13 (2.5) 72 (3.6) 0.67 (0.37-1.23) 
 Systemic steroids 199 (46.0) 617 (38.4) 1.38 (1.11-1.72)  271 (51.3) 843 (41.7) 1.50 (1.23-1.82) 
Abbreviations: OR – odds ratio, CI – confidence interval, sd – standard deviation,  
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TABLE 4.4.2  CHARACTERISTICS OF CASES WITH INCIDENT PEPTIC ULCER AND THEIR CONTROLS 
 MEN  WOMEN 
 Cases (%) 
n=140 
Controls (%) 
n=560 
OR (95% CI)  Cases (%) 
n=107 
Controls (%) 
n=428 
OR (95% CI) 
Mean age (years) ± sd 71.8±8.0 71.5±7.8 --  69.9±9.6 69.7±9.4 -- 
BMI (kg/m2) 
 <17.5  
 17.5-24.9 
 25.0-29.9 
 ≥30 
 unknown 
5 (3.6) 
41 (29.3) 
56 (40.0) 
19 (13.6) 
19 (13.6) 
12 (2.1) 
169 (30.2) 
197 (35.2) 
93 (16.6) 
89 (15.9) 
1.67 (0.57-5.00) 
1.00 (ref) 
1.15 (0.74-1.80) 
0.84 (0.45-1.56) 
0.87 (0.46-1.63) 
 
6 (5.6) 
26 (24.3) 
38 (35.5) 
18 (16.8) 
19 (17.8) 
15 (3.5) 
139 (32.5) 
119 (27.8) 
82 (19.2) 
73 (17.1) 
2.09 (0.73-6.02) 
1.00 (ref) 
1.71 (0.97-3.02) 
1.20 (0.62-2.32) 
1.39 (0.68-2.85) 
Smoking status 
 Non-smokers 
 Smokers 
 Ex-smokers 
 unknown 
50 (35.7) 
40 (28.6) 
44 (31.4) 
6 (4.3) 
191 (34.1) 
109 (19.5) 
223 (39.8) 
37 (6.6) 
1.00 (ref) 
1.41 (0.87-2.29) 
0.73 (0.46-1.18) 
0.55 (0.20-1.53) 
 
37 (34.6) 
38 (35.5) 
27 (25.2) 
5 (4.7) 
195 (45.6) 
107 (25.0) 
87 (20.3) 
39 (9.1) 
1.00 (ref) 
1.94 (1.14-3.30) 
1.61 (0.91-2.84) 
0.34 (0.07-1.58) 
GORD 16 (11.4) 50 (8.9) 1.34 (0.72-2.47)  12 (11.2) 52 (12.2) 0.90 (0.45-1.83) 
Drug exposure        
 NSAIDs 113 (80.7) 424 (75.7) 1.38 (0.58-2.23)  88 (82.2) 331 (77.3) 1.39 (0.79-2.44) 
 Vitamin K antagonists 10 (7.1) 44 (7.9) 0.90 (0.44-1.84)  11 (10.3) 22 (5.1) 2.19 (1.00-4.80) 
 Systemic steroids 54 (38.6) 235 (42.0) 0.87 (0.59-1.27)  51 (47.7) 193 (45.1) 1.12 (0.72-1.74) 
Abbreviations: OR – odds ratio, CI – confidence interval, sd – standard deviation,  
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Incidence rates of GORD and ulcer were higher among COPD patients (59.2 and 14.8 per 
10,000 py, respectively) than among patients in the COPD-free comparison group (44.4 and 
10.8 per 10,000 py, respectively). Incidence rates of GORD were higher in women compared 
to men in COPD and COPD-free patients while incidence rates of peptic ulcer were higher 
for men. The IRs and IRRs for the two outcomes of interest, stratified by sex, are displayed in 
Table 4.4.3. 
 
 
TABLE 4.4.3  INCIDENCE RATES OF GORD AND PEPTIC ULCER IN COPD AND COPD-FREE PATIENTS 
 Cases Person-time 
(years) 
IR per 10,000 py 
(95% CI) 
IRR 
IRR 95% CI 
 
GORD 
      
COPD-free 
 Men 
 Women 
COPD 
 Men 
 Women 
450 
195 
255 
511 
238 
273 
101361.7 
50697.5 
50664.2 
86305.9 
42795.5 
43510.4 
44.4 (40.5-48.7) 
38.5 (33.4-44.2) 
50.3 (44.5-56.9) 
59.2 (54.3-64.6) 
55.6  (49.0-63.1) 
62.7  (55.8-70.6) 
 
0.77 (0.64-0.92) 
1.00 (ref) 
 
0.89 (0.75-1.05) 
1.00 (ref) 
 
ULCER 
      
No COPD 
 Men 
 Women 
COPD 
 Men 
 Women 
114 
63 
51 
133 
77 
56 
105781.0 
51251.6 
54529.4 
89946.2 
43159.0 
46787.1 
10.8 (9.0-12.9) 
12.3 (9.6-15.7) 
9.4 (7.1-12.3) 
14.8  (12.5-17.5) 
17.8  (14.3-22.3) 
12.0  (9.2-15.5) 
 
1.31 (0.91-1.90) 
1.00 (ref) 
 
1.49 (1.06-2.09) 
1.00 (ref) 
Abbreviations: IR: incidence rate, CI: confidence interval; py: person years 
 
 
In order to evaluate the effects of COPD severity on the study outcomes we conducted a 
nested case-control analysis where we stratified COPD patients according to treatment into 
mild, moderate or severe COPD. Differences in the risk of developing GORD or ulcer in 
relation to COPD severity were small. The relative risk of developing GORD was not 
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materially altered in women with COPD compared to women without COPD and did not show 
a significant association with COPD severity. In men the GORD risk was highest in patients 
with mild COPD. The peptic ulcer risk was statistically significantly increased in male patients 
with moderate COPD while in female patients there was a tendency towards an increased 
risk in severe COPD although it was not statistically significant and based on only 6 women. 
The detailed findings for the various associations between COPD and gastrointestinal 
outcomes, stratified by COPD severity, are displayed in Table 4.4.4.  
In order to evaluate the effects of beta agonists on the risk of peptic ulcer we compared 
COPD patients using beta agonist with patients not using them. In total 125 COPD patients 
used long-acting beta 2 agonists and 21 of them developed an ulcer yielding a crude risk 
estimate of 0.62 (95% CI 0.37-1.05). Risks in men and women were closely similar. Stratified 
by the timing of long-acting beta agonist exposure we found a protective association between 
current exposure within the last 60 days and the risk of an ulcer diagnosis of 0.38 (0.16-
0.93), again the risk estimates in men and women were closely similar but the stratified 
analysis was not statistically significant. Current exposure to short-acting beta agonists was 
not associated with a protective effect. The detailed findings stratified by gender and timing 
of exposure are displayed in Table 4.4.5. 
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TABLE 4.4.4  RISK OF GORD AND PEPTIC ULCER STRATIFIED BY COPD SEVERITY IN MEN AND WOMEN 
 GORD Ulcer disease 
 Cases 
 
Controls 
 
Crude OR 
(95% CI) 
Adj. * OR 
(95% CI) 
Cases 
 
Controls 
 
Crude OR 
(95% CI) 
Adj. * OR 
(95% CI) 
No COPD 
 Men 
 Women 
450 
195 
255 
1931 
833 
1098 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
114 
63 
51 
533 
301 
232 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
Any COPD 
 Men 
 Women 
511 
238 
273 
1697 
775 
922 
1.27 (1.11-1.46) 
1.29 (1.05-1.59) 
1.26 (1.05-1.52) 
1.19 (1.00-1.40) 
1.29 (1.00-1.67) 
1.14 (0.90-1.43) 
133 
77 
56 
455 
259 
196 
1.34 (1.02-1.76) 
1.38 (0.97-1.97) 
1.28 (0.85-1.94) 
1.24 (0.92-1.66) 
1.41 (0.96-2.07) 
1.01 (0.63-1.62) 
 Mild 
 Men 
 Women 
41 
26 
15 
116 
56 
60 
1.52 (1.05-2.21) 
2.01 (1.23-3.28) 
1.07 (0.60-1.92) 
1.66 (1.13-2.44) 
2.25 (1.35-3.77) 
1.16 (0.64-2.11) 
8 
6 
2 
41 
27 
14 
0.89 (0.41-1.94) 
1.04 (0.42-2.62) 
0.64 (0.14-2.83) 
0.82 (0.37-1.83) 
0.99 (0.38-2.58) 
0.44 (0.09-2.16) 
 Moderate 
 Men 
 Women 
453 
205 
248 
1528 
695 
833 
1.25 (1.09-1.45) 
1.24 (1.00-1.54) 
1.27 (1.05-1.54) 
1.14 (0.95-1.35) 
1.20 (0.92-1.56) 
1.13 (0.89-1.43) 
119 
68 
51 
397 
218 
179 
1.37 (1.04-1.82) 
1.45 (1.00-2.11) 
1.28 (0.84-1.96) 
1.26 (0.93-1.71) 
1.84 (1.18-2.87) 
1.07 (0.62-1.86) 
 Severe 
 Men 
 Women 
17 
7 
10 
53 
24 
29 
1.36 (0.78-2.37) 
1.25 (0.53-2.96) 
1.45 (0.70-3.01) 
1.22 (0.68-2.18) 
1.17 (0.48-2.86) 
1.40 (0.64-3.03) 
6 
3 
3 
17 
14 
3 
1.62 (0.61-4.32) 
0.96 (0.26-3.56) 
4.41 (0.88-22.10) 
1.66 (0.60-4.61) 
1.57 (0.39-6.40) 
3.78 (0.61-23.40) 
* GORD analyses are adjusted for smoking status, BMI, systemic steroid use and NSAID use; further adjustment for cox-2 inhibitor use did 
not have a major impact on the results; ulcer analyses are adjusted for smoking status, BMI, NSAID use, GORD, vitamin K antagonist use; 
Adj.: adjusted; CI: confidence interval; OR: odds ratio; ref: reference 
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TABLE 4.4.5  USE OF BETA AGONISTS AND THE RISK OF PEPTIC ULCER IN MEN AND WOMEN 
 
Cases 
 # 
Controls 
# 
Crude OR  
(95% CI) 
Adj. OR  
(95% CI) 
P-
value 
Controls 
     
all 114 533 0.54 (0.35-0.83) 0.58 (0.37-0.91) 0.02 
  Men 63 301 0.45 (0.27-0.77) 0.48 (0.27-0.83) 0.01 
  Women 51 232 0.75 (0.35-1.61) 0.85 (0.37-1.95) 0.69 
Long-acting beta agonists 
unexposed 112 351 1.00 (ref) 1.00 (ref) -- 
  Men 64 194 1.00 (ref) 1.00 (ref) -- 
  Women 48 157 1.00 (ref) 1.00 (ref) -- 
<60 days 7 54 0.41 (0.17-0.97) 0.38 (0.16-0.93) 0.03 
  Men 3 32 0.35 (0.10-1.27) 0.33 (0.09-1.25) 0.10 
  Women 4 22 0.51 (0.16-1.69) 0.39 (0.11-1.46) 0.16 
60-364 days 9 23 1.35 (0.59-3.12) 1.35 (0.57-3.18) 0.50 
  Men 6 16 1.26 (0.42-3.80) 1.40 (0.45-4.38) 0.57 
  Women 3 7 1.45 (0.33-6.35) 1.42 (0.28-7.37) 0.67 
≥ 1 year 5 27 0.59 (0.21-1.70) 0.63 (0.21-1.87) 0.40 
  Men 4 17 0.94 (0.26-3.39) 1.11 (0.30-4.18) 0.87 
  Women 1 10 0.22 (0.02-2.11) 0.20 (0.02-1.94) 0.16 
Short-acting beta agonists 
unexposed 43 112 1.00 (ref) 1.00 (ref) -- 
  Men 31 74 1.00 (ref) 1.00 (ref) -- 
  Women 12 38 1.00 (ref) 1.00 (ref) -- 
<60 days 52 193 0.85 (0.47-1.55) 0.82 (0.44-1.52) 0.52 
  Men 25 106 0.87 (0.39-1.94) 0.91 (0.40-2.11) 0.83 
  Women 27 87 1.06 (0.39-2.87) 0.96 (0.33-2.77) 0.94 
60-364 days 21 78 0.68 (0.34-1.36) 0.65 (0.32-1.34) 0.25 
  Men 12 35 0.88 (0.36-2.11) 0.97 (0.39-2.43) 0.94 
  Women 9 43 0.56 (0.17-1.84) 0.54 (0.15-1.92) 0.34 
≥ 1 year 17 72 0.61 (0.30-1.25) 0.58 (0.28-1.22) 0.15 
  Men 9 44 0.52 (0.20-1.33) 0.49 (0.18-1.32) 0.16 
  Women 8 28 0.73 (0.23-2.32) 0.68 (0.20-2.34) 0.54 
Crude ORs are adjusted for all variables in the table, short-acting anticholinergics, tiotropium, 
xanthines and inhaled steroids use. Adj ORs are in addition adjusted for all variables in the table 
and BMI, smoking status, NSAID use, GORD and vitamin K antagonist use. 
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4.4.5  DISCUSSION 
The GORD incidence rates we found are similar to incidence rates reported in two other 
studies investigating the frequency of GORD in the general population.(183, 184) Our GORD 
incidence in the COPD population, however, is lower than recently reported by Garcia 
Rodriguez et al.. Different case definitions might explain this difference, for example, we 
excluded patients with a history of PPI or histamine 2 receptor antagonists use.(185) We did 
not observe an increasing risk of GORD with increasing COPD severity, which is in contrast 
to previous reports of a higher risk of reflux oesophagitis among patients with severe COPD 
and a higher GORD prevalence in more severe COPD.(186-189) Ruigomez et al., who 
investigated the natural history of GORD, also reported that COPD was only weakly 
associated with GORD (OR: 1.3 [1.0-1.8] 95% CI), which is similar to our results.(183) They 
also found slightly higher incidence rates in women than in men in COPD patients. Other 
settings not restricted to COPD reported inconclusive results with respect to gender 
differences.(190, 191) 
There was only a weak association between COPD and ulcer disease, a smaller association 
than was reported in studies analysing the association between ulcer and COPD back in the 
1960s and 1970s. Most of these studies investigated the association between ‘emphysema’ 
and ulcer, and it was hypothesized that pulmonary emphysema may change the ‘blood acid 
balance’, thereby increasing the ‘acid attack factors’ and causing peptic ulceration.(171, 172) 
Since then, a decrease in peptic and duodenal ulcer cases was observed (175, 192). 
Currently, Helicobacter pylori infection, NSAID use and tobacco smoking are thought to be 
the main risk factors for ulcer.(123, 176) Only a few recent studies investigated the 
association between COPD and ulcer. A Danish study assessed the association between 
COPD and 30-day mortality of severe peptic ulcer (i.e. hospitalization-requiring perforated or 
bleeding ulcers) and reported that COPD was associated with less favourable 
outcomes.(173) A recent, cross-sectional, American study based on self-reported data 
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reported a crude increased risk of GI ulcer disease in patients with COPD compared to 
COPD-free patients (OR: 2.34 [2.21-2.47] 95% CI).(174) 
We found an incidence rate of ulcer disease of 14.8 / 10,000 person-years (py) among 
COPD patients, which was slightly higher than the 10.8 / 10,000 py among COPD-free 
patients. Incidence rates in men were slightly higher than incidence rates in women in both 
patients with and patients without COPD. Male sex has also before been reported to be a 
risk factor for peptic ulcer.(193) Kang et al. analysed the period prevalence of peptic 
ulceration in England and Wales between 1994 and 1998 and reported falling age-
standardized rates from 3.3 and 1.8 / 1000 male or female patients, respectively, in 1994 to 
1.5 and 0.9 / 1000 in male and female patients, respectively, in 1998.(175) In Belgium, 
incidence rates of duodenal and gastric ulcer were also reported to be decreasing between 
1994 and 2003; the age-standardized rates for gastric ulcer decreased from 2.22 (1.94-2.50) 
in 1994/95 to 0.85 (0.70-1.00) in 2002/03 (per 1000 patient years), and rates for duodenal 
ulcer decreased from 1.75 (1.50-2.00)  to 1.01 (0.84-1.18) (per 1000 patient years) in the 
same period.(192) Women, however, seem to be slightly younger at their first peptic ulcer 
diagnosis than men. 
Current exposure to long-acting beta agonists was associated with a decreased risk of an 
ulcer diagnosis (OR 0.38, 95% CI 0.16-0.93) with similar results in men and women while 
current short-acting beta agonist exposure was not associated with the risk of an ulcer 
diagnosis. Animal studies suggested that the beta adrenergic system might be involved in 
the control of gastric acid secretion. The receptor involved is, however, not a beta 2 
adrenergic receptor but a beta 3 adrenergic receptor. Selective agonists of beta 3 receptor 
have shown promising effects in animal studies of gastric ulcer.(177-179) Beta 2 agonists 
have also proven some protective effects in rats and cats. In a study in cats clenbuterol, a 
beta 2 agonist, and SR58611A have been compared, both had gastro-protective effects but 
the effects of clenbuterol could be prevented by the addition of propanolol, a beta 
blocker.(180) Animal studies in rats showed that terbutaline, a beta 2 agonist, reduced 
indomethacin-induced gastric ulceration.(182) Salbutamol has also been reported to confer 
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protective effects.(181) To our knowledge this is the first study showing this effect in humans. 
Why this effect is only observed with long-acting beta agonists is not clear but might be 
explained by the longer half life. The analysed study population, however, is small and thus 
the results need to be interpreted with caution. Further research is needed to evaluate 
whether beta 2 agonist indeed have a protective effect in humans. 
We adjusted all analyses on the risk of developing GORD or ulcer for the potential 
confounders smoking and NSAID use. We accounted for the possible role of alcohol abuse 
by excluding patients with known alcoholism from the analysis. We also tried to adjust for 
Helicobacter pylori infections but had only limited information so that we could not include 
this factor in the analyses. Despite these efforts we cannot fully exclude residual confounding 
by smoking, Helicobacter pylori infection and/or drinking when reporting the results for the 
analyses on COPD and ulcer risk.  
It is both a strength and a limitation of the current study that diagnoses were based on GP-
recorded diagnoses. It is a strength because all diagnoses in the GPRD are recorded on a 
routine basis and independently from any study hypothesis, which is superior to interview-
based assessments of diagnoses with a particular study hypothesis in mind. On the other 
hand, we cannot rule out a certain amount of misclassification for both COPD and the 
gastrointestinal outcomes of interest. Some diagnoses may have been missed due to 
underreporting of symptoms to the GP (e.g. for mild forms of COPD), or because patients 
may have treated themselves (e.g. antacids for GORD, which are available over the 
counter). Thus, reported incidence rates for these outcomes might be underestimated to 
some degree. This might also affect the comparison of incidence rates between men and 
women if there is a difference in reporting symptoms to their GP. Other diagnoses may be 
slightly overrepresented in COPD patients, for example because COPD patients may have a 
higher likelihood of getting a diagnosis recorded because they may see the GP more often. 
Thus, these results represent incidence rates of GP-recorded GORD in ulcer in the UK 
primary-care setting based on a large, well validated database which has been used for 
previous published studies on COPD, ulcer and GORD.(84, 175, 183) 
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4.5  CANCER RISK IN PATIENTS WITH COPD  
 
4.5.1  ABSTRACT 
The aim of this study was to compare the risk of developing cancer between patients with or 
without COPD, and to assess the role of gender on the risk of developing lung cancer in 
COPD patients. We used the UK-based General Practice Research Database to conduct a 
follow-up study with a nested case-control analysis. We identified all patients with an incident 
COPD diagnosis aged 40-79 years between 1995 and 2005 and a matched COPD-free 
comparison group. We then identified all patients who received an incident cancer diagnosis 
during follow-up. Among 35,772 COPD patients and 35,772 COPD-free patients, we 
identified 4506 patients with an incident cancer diagnosis, of whom 2585 (57.4%) had a 
previous COPD diagnosis, yielding a crude incidence rate ratio of 1.64 (95% CI 1.55-1.74). 
The increased risk was mainly driven by a high lung cancer risk among COPD patients. In 
the nested case-control analysis, the odds ratio (OR) for lung cancer associated with COPD 
was higher for women (OR 5.26, 95% CI 3.64-7.61) than for men (OR 2.10, 95% CI 1.70-
2.60). Our findings provide further evidence that COPD is associated with an elevated lung 
cancer risk, and that women with COPD may be more susceptible to developing lung cancer 
than men.  
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4.5.1  INTRODUCTION 
According to the ‘Global Initiative for Obstructive Lung Diseases’ (GOLD), chronic obstructive 
pulmonary disease (COPD) is associated with an abnormal inflammatory response of the 
lungs which is accompanied by a not fully reversible airflow limitation.(27) The pronounced 
chronic inflammatory process is thought to increase the risk for lung cancer due to constant 
tissue damage and exposure to substances with mutagenic potential such as reactive 
oxygen species.(194, 195) For other organ systems, similar associations between chronic 
inflammation and cancer have been discussed, such as inflammatory bowel disease (IBD) 
and colon cancer,(196) chronic hepatitis and liver cancer,(197) or human papilloma virus 
(HPV-16 and HPV-18) infection and anogenital carcinoma.(198) Asthma is another major 
obstructive lung disease with substantial inflammation; although studies on the association 
between asthma and lung cancer reported conflicting results, pooled estimates did not 
provide evidence for an association between asthma and an increased cancer risk.(199-201)  
Previous studies on the association between COPD and cancer risk mainly focused on lung 
cancer, suggesting that COPD increases the risk for lung cancer materially.(202, 203)  
COPD patients and lung cancer patients share an important risk factor, which is smoking. 
Men have been reported to have higher COPD rates than females, which may be attributed 
to higher smoking rates in males compared to females in the past, but smoking rates as well 
as COPD rates in females have been reported to rise.(84) In addition, studies indicated that 
female smokers might be more susceptible to developing COPD than male smokers, as 
women with COPD tended to suffer from a greater reduction in FEV1.(99)  
In this study we explored the association between COPD and the risk of developing cancer 
stratified in men and women. 
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4.5.3  METHODS 
For detailed information on the database and study design please refer to the general 
methods section here only the information on the exclusion criteria, case validation and 
statistical analyses are repeated.  
Exclusion Criteria: All patients with a history of cancer except for non-melanoma skin 
cancer were excluded. 
Case definition: All patients with a code for cancer were identified. 
Statistical Analyses: We provided the risks estimates stratified for different cancer sites and 
adjusted for patient characteristics such as body mass index (BMI (<18.5, 18.5-25, 25-29.9, 
30-60 kg/m2, or unknown), smoking history (no, current, past, unknown), as well as for 
various cancer type specific confounders (breast cancer: contraceptive use, hormone 
replacement therapy use, benign neoplasms, non-melanoma skin cancer, and NSAID use; 
lymphoma: benign neoplasms, use of carcinogenic drugs; gastro-oesophageal cancer: 
gastro-oesophageal reflux disease, benign neoplasms, non-melanoma skin cancer; 
colorectal cancer: NSAID use, constipation, benign neoplasms, non-melanoma skin cancer; 
female reproductive system cancer: contraceptive use, hormone replacement therapy use, 
benign neoplasm, non-melanoma skin cancer, NSAID use; urinary system cancers: 
hypertension, benign neoplasms, use of diuretics, use of carcinogenic drugs, urinary 
dysfunction). 
 
4.5.4  RESULTS 
Within the study population, we identified a total of 4506 cancer cases during follow-up, 2585 
among the COPD patients and 1921 among the COPD-free patients. The incidence rates 
(IR) were 27.8 / 1000 person-years (py) among COPD-patients, and 16.8 / 1000 py among 
COPD-free patients. IR were higher among men than among women, but the incidence rate 
ratio (IRR) associated with COPD was slightly higher in females than in males. The cancer IR 
increased with age. Details on cancer IRs are displayed in Table 4.5.1. 
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TABLE 4.5.1  INCIDENCE RATES OF CANCER IN COPD AND COPD-FREE PATIENTS  
 
Cases 
 
Person-time 
(years) 
IR per 1000 py 
(95% CI) 
IRR 
(95% CI) 
COPD-free 
 Men 
 Women 
COPD 
 Men 
 Women 
1921 
1207 
714 
2585 
1526 
1059 
114441.4 
56919.3 
57522.1 
92923.9 
45642.3 
47281.7 
16.8 (16.1 – 17.5)  
21.2 (20.1 – 22.4)  
12.4 (11.5 – 13.4)  
27.8 (26.8 – 28.9) 
33.4 (31.8 – 35.1) 
22.4 (21.1 – 23.8) 
 
1.00 (ref) 
1.69 (1.55-1.85) 
 
1.00 (ref) 
1.48 (1.37-1.59) 
IR: incidence rate; IRR: incidence rate ratio; CI: confidence interval; py: person years 
 
 
In the nested case-control analysis we explored the association between a history of COPD 
and the risk of developing various types of cancer, stratified by gender. The results are 
displayed in Tables 4.5.2 and 4.5.3. The relative risk was highest for developing lung cancer 
and it was particularly high in women; OR 5.26 (95% CI 3.64-7.61), compared to men: OR 
2.10 (95% CI 1.70-2.60) (P<0.001). The risks were highest in patients with severe COPD 
receiving oxygen therapy OR 4.96 (95% CI 3.05-8.07) in men and OR 7.54 (95% CI 3.78-
15.05) in women. The risk of developing urinary / kidney cancer (in both men and women) 
was also increased, while the relative risk of developing one of the other cancer types was 
not or only marginally altered in association with a previous COPD diagnosis.  
To further analyze the association between COPD and lung cancer we did an analysis 
stratified by smoking status. The presence of COPD increased the risk of being diagnosed 
with lung cancer in non-smokers OR 4.21 (95% CI 2.65-6.69), OR 9.45, (95% CI 3.87-23.07) 
in women compared to 3.00 (95% CI 1.71-5.24) in men. The results of this analysis stratified 
by gender are provided in detail in Table 4.5.4. 
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TABLE 4.5.2  CANCER RISK IN MEN STRATIFIED BY CANCER LOCALIZATION 
 
Cases 
(N=1643) 
Controls 
(N=6572) 
OR 
 (95% CI) 
Adj. OR  
(95% CI) 
Gastro-oesophageal  cancers 
  No COPD 
  COPD 
63 
58 
264 
220 
1.00 (ref) 
1.09 (0.75-1.60) 
1.00 (ref) 
1.03 (0.69-1.54) 
Intestinal cancers 
  No COPD 
  COPD 
90 
93 
390 
342 
1.00 (ref) 
1.17 (0.85-1.60) 
1.00 (ref) 
1.24 (0.88-1.74) 
Lymphoma 
  No COPD 
  COPD 
34 
38 
137 
151 
1.00 (ref) 
1.01 (0.61-1.68) 
1.00 (ref) 
1.01 (0.61-1.68) 
Male genital cancers 
  No COPD 
  COPD 
270 
231 
1066 
938 
1.00 (ref) 
0.97 (0.81-1.18) 
1.00 (ref) 
1.01 (0.83-1.24) 
Urinary / Kidney cancers 
  No COPD 
  COPD 
95 
121 
444 
420 
1.00 (ref) 
1.34 (0.99-1.80) 
1.00 (ref) 
1.08 (0.75-1.57) 
Lung cancer 
  No COPD 
  COPD 
146 
404 
1172 
1028 
1.00 (ref) 
2.93 (2.40-3.59) 
1.00 (ref) 
2.10 (1.70-2.60) 
Abbreviations: OR – odds ratio, CI – confidence interval, OR adjusted for potential 
confounders as stated in the methods. 
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TABLE 4.5.3  CANCER RISK IN WOMEN STRATIFIED BY CANCER LOCALIZATION 
 
Cases 
(N=1007) 
Controls 
(N=4028) 
OR  
(95% CI) 
Adj. OR  
(95% CI) 
Gastro-oesophageal  cancers 
  No COPD 
  COPD 
19 
26 
93 
87 
1.00 (ref) 
1.44 (0.75-2.76) 
1.00 (ref) 
0.92 (0.43-1.98) 
Intestinal cancers 
  No COPD 
  COPD  
51 
63 
233 
223 
1.00 (ref) 
1.28 (0.85-1.91) 
1.00 (ref) 
1.14 (0.73-1.77) 
Lymphoma 
  No COPD 
  COPD 
24 
18 
89 
79 
1.00 (ref) 
0.86 (0.45-1.65) 
1.00 (ref) 
0.86 (0.45-1.65) 
Breast cancer     
  No COPD 
  COPD 
170 
167 
687 
661 
1.00 (ref) 
1.02 (0.81-1.28) 
1.00 (ref) 
1.06 (0.82-1.38) 
Female genital cancers 
  No COPD 
  COPD 
53 
35 
184 
168 
1.00 (ref) 
0.74 (0.47-1.17) 
1.00 (ref) 
0.82 (0.48-1.37) 
Urinary / Kidney cancers 
  No COPD 
  COPD 
22 
38 
125 
115 
1.00 (ref) 
1.86 (1.04-3.33) 
1.00 (ref) 
1.88 (0.83-4.27) 
Lung cancer 
  No COPD 
  COPD 
41 
280 
733 
551 
1.00 (ref) 
8.35 (5.90-11.8) 
1.00 (ref) 
5.26 (3.64-7.61) 
Abbreviations: OR – odds ratio, CI – confidence interval, OR adjusted for potential 
confounders as stated in the methods. 
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TABLE 4.5.4  LUNG CANCER RISK STRATIFIED BY SMOKING STATUS 
 Cases Controls Crude OR (95% CI) Adj. OR (95% CI) 
No COPD 
 Non-smoker 
   Men 
   Women 
 Current Smoker 
   Men 
   Women 
 Ex-smoker 
   Men 
   Women 
 
32 
25 
7 
85 
62 
23 
60 
54 
6 
 
959 
525 
434 
281 
187 
94 
446 
326 
120 
 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
9.23 (6.00-14.21) 
7.27 (4.42-11.95) 
15.03 (6.17-36.61) 
3.99 (2.55-6.24) 
3.48 (2.12-5.73) 
2.72 (0.89-8.32) 
 
1.00 (ref) 
1.00 (ref) 
1.00 (ref) 
9.04 (5.87-13.94) 
7.02 (4.26-11.58) 
15.69 (6.40-38.47) 
4.13 (2.63-6.46) 
3.59 (2.18-5.92) 
2.94 (0.97-8.95) 
COPD 
 Non-smoker 
   Men 
   Women 
 Current Smoker 
   Men 
   Women 
 Ex-smoker 
   Men 
   Women 
 
52 
30 
22 
337 
186 
151 
248 
158 
90 
 
339 
195 
144 
545 
325 
220 
581 
438 
143 
 
4.26 (2.69-6.76) 
3.02 (1.735.27) 
9.18 (3.79-22.25) 
17.19 (11.77-25.09) 
11.37 (7.32-17.65) 
40.61 (18.46-89.35 
11.48 (7.81-16.86) 
6.96 (4.48-10.80) 
35.52 (18.80-79.84) 
 
4.21 (2.65-6.69) 
2.99 (1.71-5.24) 
9.45 (3.87-23.07) 
16.25 (11.10-23.78) 
10.59 (6.79-16.50) 
40.61 (18.30-90.10) 
11.62 (7.90-17.09) 
6.95 (4.47-10.81) 
39.50 (17.78-89 
Abbreviations: OR – odds ratio, CI – confidence interval, OR adjusted for BMI and all 
variables in the table. 
 
 
4.5.5  DISCUSSION 
In this large population-based study, the overall cancer risk was increased in COPD patients 
as compared to COPD-free patients. This increased risk was mainly driven by the increased 
lung cancer risk. There was also a suggestion of an increased cancer risk for cancers of the 
urinary and the gastrointestinal tract, but after adjusting for smoking and other covariates the 
risk estimates no longer reached statistical significance. Smoking is the most important risk 
factor for both COPD and lung cancer, and it is likely that most of the observed lung cancer 
risk is due to smoking. However, stratification by smoking status showed that COPD 
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increased the risk in non-smokers, when comparing non-smoking COPD patients with non-
smoking patients without COPD, which indicates an independent contribution of COPD on 
the lung cancer risk. This proposition is consistent with findings from previous studies 
reporting risk estimates ranging from 1.5 to 2.7 for various levels of COPD severity.(202, 
203) Nevertheless our results can still be biased by residual confounding, for example, driven 
by a potential misclassification of tobacco exposure, i.e. a patient being recorded as non-
smoker although he or she is an ex-smoker. 
Overall the distribution of various cancer types in the current study population reflects what is 
known from cancer statistics: in men, lung cancer and cancer of the reproductive system 
(mainly prostate cancer) are the most frequent cancer types, followed by colorectal cancer; in 
women, lung, breast and colorectal cancer are the most common malignancies. We 
observed higher relative lung cancer risk estimates associated with a history of COPD for 
women than for men; whether this finding points towards a greater susceptibility for women, 
or whether it is due to other factors needs to be further explored. 
An important limitation of this study is the limited follow-up time between the first COPD 
diagnosis and the incident cancer diagnosis. Both COPD and cancer are chronic diseases, 
which develop and are present for some time before first symptoms become clinically 
manifest. Thus, we may have missed a certain proportion of patients with mild COPD who 
had not yet been diagnosed by the GP. Further, the proportion of patients with severe COPD 
may be small due to limited follow-up. Thus, the current study population may reflect a 
patient population with a relatively high proportion of moderate COPD. In addition it would 
have been desirable to have more information on potential risk factors or protective factors 
for certain cancers, such as former use of oral contraceptives or human papilloma virus 
infections. We assessed OC use prior to the index date for women in the nested case-control 
analysis and adjusted the analyses for this parameter, but for elderly women the likelihood of 
having previous OC use recorded on computer was of course low. By matching cancer cases 
and controls on practice, we made an attempt to take socioeconomic status into account to 
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some degree, as social deprivation shows a geographical pattern and therefore people from 
the same neighbourhood are more likely to see the same GP. 
A strength of this study is that the GPRD is a well-validated data source with a high validity of 
recorded drug exposure. In addition, all drug use was recorded prior to these analyses and in 
the absence of any study hypothesis. Further we classified drug use in all patients (i.e. cases 
or controls, or patients with or without COPD) in the same way, so that any exposure 
misclassification should be non-differentially distributed across users of various COPD 
medications. 
In summary, this observational study provides further evidence that COPD is only marginally 
or not at all associated with most cancers except lung cancer. The risk of developing lung 
cancer is substantially increased for COPD patients, which can be in part explained by 
smoking as major common underlying risk factor, but an independent association between 
chronic lung inflammation due to COPD and an increased cancer risk beyond the effect of 
smoking is also possible. In our study population, the risk of developing lung cancer in 
association with COPD was higher in women than in men.  
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4.6  COPD AND RISK OF DEPRESSION 
 
4.6.1  ABSTRACT 
Chronic co-morbidities are often associated with depression. Most previous studies exploring 
the association between COPD and depression were rather small and based on a cross-
sectional study design. We conducted a large population-based study on the risk of 
developing an incident depression diagnosis in association with a previous COPD diagnosis. 
We used the UK-based General Practice Research Database to assess and compare the 
prevalence of a history of depression, and to quantify the risk of developing incident 
depression in patients with COPD and COPD-free patients between 1995 and 2005. We 
conducted a nested case-control analysis, matching up to four patients who did not develop 
depression for each case patient with depression, to further analyze the impact of COPD 
severity. In a study population of 35,722 COPD patients and 35,722 COPD-free patients, the 
prevalence of diagnosed depression prior to the first COPD diagnosis was higher in the 
COPD population (23.1%) than among COPD-free patients (16.8%). The incidence rate of a 
new onset diagnosis of depression after the first COPD diagnosis was 16.2 / 1000 person-
years (py) in the COPD group, while it was only 9.4 / 1000 py in the COPD-free comparison 
group. In the nested case-control analysis, patients with severe COPD had the highest risk of 
developing depression (OR 2.01, 95% CI 1.45-2.78).  This large observational study provides 
further evidence that patients with COPD are at an increased risk of developing depression. 
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4.6.2  INTRODUCTION 
Depression is an important public health problem worldwide.(204) The disease is often 
associated with chronic co-morbidities, which is of particular and increasing relevance in an 
ageing polymorbid society.(205) Chronic obstructive pulmonary disease (COPD) has a high 
prevalence in the elderly, and the burden of disease is expected to increase.(31)  
Observational studies investigating the association between COPD and depression reported 
a wide range of depression prevalences in COPD patients from 7% with a forced expiratory 
volume in 1 second (FEV1) <80%, up to 79.1% in COPD patients with chronic respiratory 
failure.(206, 207) The cumulative incidence has recently been reported to be 6.1%.(126) The 
risk of depression seems to be associated with COPD severity,(208, 209) but the wide range 
of depression prevalence reported in previous studies may also be related to differences in 
disease definitions and inclusion criteria. Methods used to define depression ranged from 
self-reports to diagnoses made by general practitioners (GPs) to diagnoses made by 
psychiatrists after detailed assessments, and the case classification was based on various 
coding systems such as ICD-10, DSM-III or Beck Depression Inventory.(207) 
Depression has been associated with adverse health outcomes and increased 
mortality,(210) though not all studies have found such an association.(210, 211) Authors of 
previous studies which reported an increased mortality suggested that suicide may account 
in part for the increased mortality among depressive patients.(212) The assessment of the 
impact of depression in COPD is complicated by a two-sided association; depression is 
thought to contribute indirectly to the development of COPD as depressed people are less 
likely to quit smoking, but depression can also develop as a direct or indirect consequence of 
a COPD diagnosis.(124) 
Most previous studies investigating the association between COPD and depression were 
rather small and/or based on a cross-sectional design.(207, 213) We conducted a large 
observational study using data from a primary-care setting in the UK to quantify the 
prevalence of depression in COPD patients at the time of the first COPD diagnosis and to 
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compare this prevalence to a COPD-free population, and to assess the incidence rate of 
newly diagnosed depression among COPD-patients and among a COPD-free comparison 
group. 
 
4.6.3  METHODS 
For detailed information on the database and study design please refer to the general 
methods section here only the information on the exclusion criteria, case validation and 
statistical analyses are repeated.  
Exclusion Criteria: All patients with a diagnosis of depression or suicidal ideation prior to 
the start of follow-up (i.e. the date of the first COPD diagnosis or the corresponding date in 
the controls) were excluded. 
Case definition: All patients with a recorded depression were identified. For a sensitivity 
analysis we identified patients with a recorded depression, who received at least 1 
prescription for selective serotonin reuptake inhibitors (SSRI), monoamine reuptake inhibitors 
(MNRI), monoaminooxidase A inhibitors (MAOA) or other antidepressive drugs within half a 
year around the depression diagnosis and who did not have prescriptions for the above 
mentioned drugs prior to the COPD index date.  
Statistical Analyses: Depression analyses were adjusted for smoking status, BMI, serious 
infections, sleeping disorders and cardiovascular diseases (deep vein thrombosis, pulmonary 
embolism, ischemic heart disease, or stroke / TIA). In addition to analyzing all cases with an 
incident diagnosis of depression, we also conducted sensitivity analyses in which we only 
included cases with an incident depression diagnosis followed by specific pharmacological 
treatment, i.e. those who received at least one prescription for selective serotonin reuptake 
inhibitors (SSRI), monoamine reuptake inhibitors (MNRI), monoaminooxidase A inhibitors 
(MAOA), or another antidepressive agent within 6 months of the depression diagnosis (and 
who had no such treatment prior to the index date). We further assessed the time between 
the first COPD diagnosis and the first depression diagnosis in two-year intervals and 
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explored whether the risk of developing a depression diagnosis was dependent on the 
duration of COPD. We stratified this conditional regression analysis by gender and adjusted 
for smoking status, BMI, cardiovascular diseases (pulmonary embolism, deep vein 
thrombosis, ischemic heart disease, stroke / TIA), a history of serious infections, sleeping 
disorders, and for COPD treatment (oxygen use, beta agonist use, anticholinergic use and 
use of xanthines), which have been associated with depression in univariate analyses. 
Statistical significance was set at p < 0.05. 
In addition, we assessed among patients with COPD the proportion of cases who developed 
depression and who died within one year after the depression diagnosis. We compared this 
proportion to the proportion of COPD patients who died within a year after the index date 
without having developed depression in order to assess the impact of depression on 
mortality among COPD-patients.    
 
4.6.4  RESULTS 
After excluding patients with prevalent depression, previous suicidal ideation, cancer, human 
immunodeficiency virus (HIV), drug abuse or alcoholism, we identified 2027 patients with an 
incident diagnosis of depression (65 had a diagnosis of suicidal ideation or suicide), of whom 
1174 came from the COPD group and 853 from the COPD-free comparison group. The 
incidence rates of diagnosed depression were 16.2 / 1000 person-years (py) in the COPD 
group, and 9.4 / 1000 py in the COPD-free comparison group, yielding a crude incidence rate 
ratio (IRR) of 1.72 (95% CI 1.58-1.88). Incidence rates in women were higher than in men in 
both patients with COPD and patients without COPD. The incidence rates stratified by 
gender are displayed in Table 4.6.1. 
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TABLE 4.6.1  INCIDENCE RATES OF DEPRESSION IN COPD AND COPD-FREE PATIENTS 
 Cases Person-time 
(years) 
IR per 1000 py 
(95% CI) 
IRR (95% CI) 
COPD-free 
 Men 
 Women 
COPD 
 Men 
 Women 
853 
338 
515 
1174 
528 
646 
91214.0 
48457.3 
42756.7 
72310.0 
39473.5 
32836.5 
9.4 (8.7-10.0) 
7.0 (6.3-7.8) 
12.0 (11.1-13.1) 
16.2 (15.3-17.2) 
13.4 (12.3-14.6) 
19.7 (18.2-21.2) 
 
0.58 (0.51-0.67) 
1.00 (ref) 
 
0.68 (0.61-0.77) 
1.00 (ref) 
Abbreviations: IR: incidence rate, IRR: incidence rate ratio, CI: confidence interval; py: 
person years 
 
 
The nested case-control analysis included 2027 cases and 8108 matched controls from the 
study population; 42.7% of them were men. Their characteristics are presented in Table 
4.6.2 stratified by gender. Compared to the reference group of COPD-free patients, the 
relative risk estimate (OR) of developing an incident depression diagnosis for patients with 
COPD was 1.44 (95% CI 1.30-1.60), 1.32 (95% CI 1.15-1.52) in women and 1.62 (95% CI 
1.37-1.90) in men, after adjusting for smoking status, BMI, serious infections, sleeping 
disorders and cardiovascular diseases (deep vein thrombosis, pulmonary embolism, 
ischemic heart disease, or stroke / TIA). The relative risk of developing depression was 
highest for severe COPD patients receiving oxygen therapy (OR 2.01, 95 % CI 1.45-2.78), 
the risk being markedly increased in men (adj. OR 2.68, 95% CI 1.61-4.47) and slightly 
increased in women (adj. OR 1.63, 95% CI 1.06-2.51). Risks were almost the same in mild 
and moderate COPD in men adj. OR 1.52, 95% CI 1.05-2.20 and adj. OR 1.58, 95% CI 1.34-
1.87) while the risk in mild COPD was not increased in women (adj. OR 0.95, 95% CI 0.65-
1.37) and slightly increased in moderate COPD (adj. OR 1.34, 95% CI1.16-1.55). 
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TABLE 4.6.2  CHARACTERISTICS OF CASES WITH INCIDENT DEPRESSION AND THEIR CONTROLS 
 MEN    WOMEN   
 
Cases (%) 
n=866 
Controls (%) 
n=3464 
OR (95% CI)  Cases (%) 
n=1161 
Controls (%) 
n=4644 
OR (95% CI) 
Mean age (years) ± sd 66.3 ± 10.3 66.3 ± 10.0 --  66.3 ± 10.5 66.3 ± 10.2 -- 
BMI (kg/m2) 
 <17.5  
 17.5-24.9 
 25.0-29.9 
 ≥30 
 Unknown 
13 (1.5) 
294 (34.0) 
254 (29.3) 
142 (16.4) 
163 (18.8) 
28 (0.8) 
1055 (30.5) 
1195 (34.5) 
513 (14.8) 
673 (19.4) 
1.69 (0.87-3.31) 
1.00 (ref) 
0.76 (0.63-0.92) 
0.99 (0.79-1.24) 
0.86 (0.69-1.08) 
 
35 (3.0) 
430 (37.0) 
308 (26.5) 
194 (16.7) 
194 (16.7) 
76 (1.6) 
1587 (34.2) 
1370 (29.5) 
814 (17.5) 
797 (17.2) 
1.70 (1.12-2.57) 
1.00 (ref) 
0.83 (0.71-0.98) 
0.88 (0.73-1.06) 
0.89 (0.73-1.09) 
Smoking status 
 Non-smokers 
 Smokers 
 Ex-smokers 
 Unknown 
218 (25.2) 
273 (31.5) 
301 (34.8) 
74 (8.6) 
1164 (33.6) 
899 (26.0) 
1050 (30.3) 
351 (10.1) 
1.00 (ref) 
1.64 (1.34-2.00) 
1.55 (1.27-1.89) 
1.09 (0.80-1.49) 
 
428 (36.9) 
371 (32.0) 
269 (23.2) 
93 (8.0) 
2210 (47.6) 
1071 (23.1) 
936 (20.2) 
427 (9.2) 
1.00 (ref) 
1.82 (1.55-2.14) 
1.49 (1.25-1.77) 
1.09 (0.83-1.44) 
COPD 
COPD (all) 
 Mild 
 Moderate 
 Severe 
528 (61.0) 
47 (5.4) 
451 (52.1) 
30 (3.5) 
1532 (44.2) 
147 (4.2) 
1342 (38.7) 
43 (1.2) 
1.91 (1.65-2.22) 
1.79 (1.26-2.53) 
1.86 (1.60-2.17) 
3.85 (2.37-6.24) 
 
646 (55.6) 
39 (3.4) 
573 (49.4) 
34 (2.9) 
1997 (43.0) 
170 (3.7) 
1745 (37.6) 
82 (1.8) 
1.62 (1.43-1.84) 
1.15 (0.80-1.65) 
1.65 (1.45-1.88) 
2.10 (1.38-3.17) 
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TABLE 4.6.2  CHARACTERISTICS OF CASES WITH INCIDENT DEPRESSION AND THEIR CONTROLS 
 MEN    WOMEN   
 
Cases (%) 
n=866 
Controls (%) 
n=3464 
OR (95% CI)  Cases (%) 
n=1161 
Controls (%) 
n=4644 
OR (95% CI) 
Co-morbidities        
 Cardiovascular diseases 324 (37.4) 968 (27.9) 1.62 (1.37-1.91)  299 (25.8) 1007 (21.7) 1.29 (1.10-1.50) 
 Serious infections 52 (6.0) 111 (3.2) 2.00 (1.39-2.76)  64 (5.5) 135 (2.9) 1.96 (1.44-2.66) 
 Sleeping disorder 206 (23.8) 337 (9.7) 3.37 (2.73-4.17)  284 (24.5) 611 (13.2) 2.29 (1.93-2.70) 
 Diabetes 96 (11.1) 306 (8.8) 1.30 (1.01-1.66)  76 (6.6) 306 (6.6) 0.99 (0.77-1.29) 
 Hypertension 263 (30.4) 1041 (30.1) 1.02 (0.86-1.20)  399 (34.4) 1584 (34.1) 1.01 (0.88-1.17) 
Abbreviations: OR – odds ratio, CI – confidence interval, sd – standard deviation, cardiovascular disease - pulmonary embolism, congestive heart 
failure, ischemic heart disease, stroke / TIA. For all diseases each disease-free status is the reference. 
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In the analysis in which we assessed the duration of a previous history of COPD among 
cases with depression and their controls (stratified by gender), the relative risk of developing 
depression was stable over time in men, i.e. independent of the duration of a previous COPD 
history. On the other hand, it tended to increase slightly with increasing COPD duration in 
women (Figure 4.3).  
Among patients with COPD, the proportion of those who died within a year of the index date 
was higher for patients with depression (9.5%) than for those who did not develop 
depression (5.4%). This difference was larger in men (12.7% vs. 5.1%) than in women (7.0% 
vs. 5.7%). In men, the increased mortality was apparent in all stages of COPD (Figure 4.4). 
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a 
 
b 
 
 
FIGURE 4.3.  RISK OF DEPRESSION STRATIFIED BY TIME SINCE COPD DIAGNOSIS 
a) male, b) female. The graph shows ORs (·) and 95% confidence intervals (|). The ORs are adjusted for smoking 
status, BMI, cardiovascular diseases and serious infections, oxygen use, beta agonist use, anticholinergics and 
xanthine use. Abbreviations: OR –odds ratio 
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a 
 
b 
 
 
FIGURE 4.4  1-YEAR MORTALITY OF COPD PATIENTS STRATIFIED BY DEPRESSION; COPD SEVERITY AND 
GENDER  
a) shows the 1-year mortality of all male COPD patients at the end of follow-up in percents stratified by COPD severity. b) 
shows the 1-year mortality of all female COPD patients at the end of follow-up in percents stratified by COPD severity 
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4.6.5  DISCUSSION 
In the follow-up analysis, we found an increased risk of developing an incident diagnosis of 
depression among COPD patients as compared to COPD-free patients, particularly in 
women, which is in line with reports from the literature showing that the lifetime prevalence of 
depression is twice as high in women as in men.(125, 126) In women we also found some 
evidence for an increasing depression risk with increasing COPD duration, while this was not 
the case in men. One possible explanation for this observation may be that men and women 
react differently to a COPD diagnosis, but it is also possible that women tend to get 
diagnosed with COPD at an earlier disease stage than men, which may lead to a longer lag 
time between the first COPD diagnosis and the first depression diagnosis.  
In our study population, depression was associated with an increased risk of mortality which 
is consistent with some reports from the literature, documenting that depression is 
associated with poorer survival after hospitalisation for COPD.(210, 214) However, not all 
previous studies reported an association between depression and mortality in COPD 
patients. A study in 137 outpatients with symptomatic disabling COPD stated no association 
between depression or quality of life and mortality in this group.(211) In contrast to a study by 
Fan et al.(215) who found an increased 3-year mortality risk, we saw an increased mortality 
in the first year after the depression diagnosis. Yohannes et al., found that in an univariate 
analysis depression was an independent predictor of 1 year mortality in patients after an 
acute exacerbation of COPD.(216) We found a difference between men and women with 
regard to the 1 year mortality which may point to differences in coping with the disease, or to 
differences in disease severity. The finding is at odds with the results of Crockett et al., who 
investigated the association between quality of life and mortality in patients with severe 
COPD, and reported that higher emotional distress was associated with mortality in women 
but not in men.(217) 
Our results are based on GP-diagnosed COPD and depression. While the GPRD has been 
extensively validated in previous studies and has proven to be of high quality, including 
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studies on COPD and depression,(218, 219) we cannot rule out the possibility that a certain 
proportion of patients with these diagnoses may have been missed, particularly those with 
mild forms of these diseases. A survey in private UK homes conducted by the ‘Office for 
National Statistics’ in 2000 reported that only 62% of people with symptoms of a depressive 
episode had spoken to their GP about it within the last year.(220) Furthermore, we could not 
classify patients with COPD and/or depression according to the disease severity with high 
reliability because scores for disease severity are not routinely recorded. However, we 
categorized COPD severity based on treatment patterns, as done in previous GPRD-based 
studies on COPD. (114) 
 
  
 
 
 
 
 
DISCUSSION 
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In recent years the awareness of gender differences in medicine in general and in particular 
in reaction on drugs has increased. However, systematic analyses are still scarce, although 
international guidelines on drug development incorporated the requirement of sex-specific 
analyses. It was the aim of this PhD thesis to contribute to the understanding of the natural 
history of COPD from a gender perspective. Detailed discussions of the findings can be 
found in the discussion sections of each study. In the following, I will put the results of this 
thesis in a gender perspective and discuss more general aspects of database research.  
 
 
5.1  COPD AND GENDER MEDICINE 
 
Coronary heart disease has long been regarded as primary male disease, even women 
themselves were long not aware that they are at risk of this disease. In 1993 a study asked 
women to estimate their risk of coronary heart disease at the age of 70, 73% estimated their 
risk to be less than one percent and 39% even estimated it to be less than 0.1%.(221) In the 
UK in 2008, 87,392 women died of circulatory system diseases and 80,846 men.(222) Data 
from the 2006 Health Survey for England suggest that “more than 1 in 3 men and around 1 in 
4 women aged 75 or older live with coronary heart disease”.(223) However, women are on 
average 10-15 years older than men at their first diagnosis of a coronary heart disease, in 
men 45 years of age or older is considered as risk factor while in women it is 55 of age or 
older. (21) We found a higher incidence of myocardial infarction in men, compared to women 
but the presence of COPD decreased the difference between men and women.  
The incidence of stroke is higher in men than in women and women tend to be older than 
men at their first stroke diagnosis.(163, 164, 224) Women have often more severe strokes 
than men, they have a higher degree of disability and a higher likelihood to die within 28 days 
of the stroke diagnosis than men.(163, 164) It is not known why there are gender differences. 
Smoking, diabetes, hypertension, obesity and reduced mobility are important risk factors in 
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men and women. It is discussed that differences in smoking and alcohol abuse might explain 
part of the differences. However, women are thought to have a greater susceptibility to the 
effects of smoking than men. Hormones have also been discussed as a reason for gender 
differences as within 10 years after the menopause women have similar rates of stroke than 
men.(21) Studies on HRT, however, showed inconclusive results.(225) We found a higher 
incidence of stroke in men compared to women in the COPD-free population, however 
women were more likely to die within 30 days than men. This gender difference is lost in 
patients with COPD. While the presence of COPD had no impact on the risk to develop 
stroke in men, COPD increased the risk of stroke in women by 1.41 (95% CI, 1.06-1.88). The 
presence of COPD increased the overall mortality, in particular the mortality in men which 
was as high as the mortality in women with and without COPD. 
Whether there is a gender difference in incidence and prevalence of VTE is controversially 
discussed.(21, 226) A systemic review of studies on the incidence of DVT published in 2003 
did not find a difference between men and women.(227) There are, however, sex-specific 
risk factors for the development of a VTE, which might explain small differences observed at 
certain age-groups. Pregnancy, use of oral contraceptives and hormone replacement therapy 
are associated with VTE in women.(226) The incidence rates of pulmonary embolism of men 
and women were closely similar in the COPD-free group and slightly higher in men with 
COPD than in women with COPD, also statistically non-significant. The incidence rates of 
DVT in the COPD-free group were slightly higher in women than in men while they were 
closely similar in men and women with COPD. Overall the impact of COPD on the incidence 
of a VTE was more important than a potential gender difference. 
Atrial fibrillation is the most common cardiac arrhythmia in developed countries, with a 
prevalence in a general population of about 0.7%, increasing up to 9% in patients over the 
age of 80 years. (228, 229) Atrial fibrillation is a major independent risk factor for 
thromboembolic events, mainly stroke and transient ischemic attacks.(230) The incidence in 
women is higher than in men but as women outnumber men in the older age-groups the 
prevalence of atrial fibrillation is almost the same in men and women.(21) We found slightly 
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higher incidence rates in men than in women in both patients with and without COPD. The 
incidence of arrhythmia was increased in patients with COPD, however, in an analysis 
adjusted for other potential risk factors we found only a non-significant association of 1.19 in 
both men and women. Women, however, tended to be slightly older than men at the 
diagnosis and patients with COPD, in particular men, tended to be slightly younger at the 
diagnosis of arrhythmia. 
There are tumours which are only found in women or men because they are localized in sex-
specific organs such as the ovary, uterus, prostate or penis. Brest cancer is mainly affecting 
women, but can also affect men. Tobacco-smoke associated tumours, such as lung cancer, 
oesophagus, kidney and bladder cancer are more often seen in men than in women but 
women are catching up. Gall bladder and thyroid cancer are more common in women while 
liver cancer is more common in men. Most other tumours have a similar distribution in men 
and women.(21) We observed a higher number of cancer cases in men, both with and 
without COPD when compared to women. COPD, however, seemed to have a greater 
impact on the risk of a cancer diagnosis in women than in men. For most cancers the risk 
was materially unchanged except for lung cancer which was materially increased in men and 
women. This association was even seen in non-smokers. Associations in women were much 
stronger than in men. In women in addition the risk of urinary and kidney cancers was 
increased although, results were statistically not significant. 
Men have historically higher numbers of peptic ulcer (231, 232) The reason for this gender 
difference is not clear. It might be due to a different risk factor profile (H.pylori infection, 
NSAID exposure, smoking status) or sex hormones. Ulcer rates in younger men are declining 
while they are increasing in the older population, particularly in women. (233) Recent 
numbers on gender differences are scarce. Men had higher incidence rates of peptic ulcer 
than women, in both patients with and without COPD. COPD did not have a strong impact on 
the risk of peptic ulcer. 
Whether there is a gender difference in the prevalence and incidence of GORD is 
controversial.(190, 191) It might be important to distinguish erosive reflux disease from non-
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erosive reflux disease. Non-erosive reflux disease is more commonly observed in women, 
although part of this difference (if not all) might be attributed to pregnancy. Erosive reflux 
disease and Barrett’s oesophagus are more common in men.(234) We found slightly higher 
incidence rates of GORD in women than in men but we could not stratify this analysis into 
erosive and non-erosive reflux disease. Differences were slightly smaller in COPD patients 
than in COPD-free patients but neither COPD nor gender had a significant impact in the risk 
of GORD. 
Women are twice as likely to develop depression as men. This difference is strongest in early 
and middle adulthood, while during childhood and in elderly, men and women are more 
equally affected by the disease. Explanations for these observed differences are diverse 
ranging from hormonal or genetic differences, over diagnostic bias to differences in social 
status. The truth might be a mixture of all of them but it is not clear. This difference is 
restricted to a first-time diagnosis of depression, recurrence is observed at similar rates in 
men and women.(21) We observed higher incidence rates of depression in women, in both 
patients with and without COPD. The impact of COPD on the risk of depression seemed to 
be slightly higher in men than in women and was highest for patients with severe COPD. In 
addition the presence of both COPD and depression had a negative impact on survival in 
men but not in women, a phenomenon which needs further investigation.  
 
 
5.2  NATURAL HISTORY OF DISEASE STUDIES 
 
Natural history of disease studies not only provide valuable information about background 
incidence rates and co-morbidities for the introduction of a new drug on the market but are 
also valuable tools for hypothesis generation regarding potential new indications of drugs. In 
this project sulfonylurea have been negatively associated with the incidence of COPD (study 
2) and long-acting beta agonists have been negatively associated with the incidence of 
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peptic ulcer (study 4). As diabetes itself is associated with a lower incidence of COPD in 
men, the association between sulfonylurea and COPD might just be a marker for the 
diabetes-COPD association. The increase of the association with increasing duration of use 
as well as the fact that no such observation is made for biguanides, however, favour a direct 
association between sulfonylurea and COPD. The fact that this association is rather seen in 
men could either mean that there is a gender-specific effect or sulfonylurea are just a marker 
for residual confounding. In the case of long-acting beta blockers the disease itself (COPD) 
had rather been positively associated with the incidence of peptic ulcer. Thus this favours a 
real association between the drug and the disease. The fact that animal studies have 
reported similar effects further supports this observation. The fact that more selective 
agonists the beta 3 agonists are in development, however, limits the importance of this 
observation. Nevertheless, it might be important for health care providers to trade the 
risk:benefit ratios of different respiratory drugs in COPD treatment, and in case this effect is 
true patients at an increased risk of ulcer might favour beta agonists. Further research is 
needed to answer the question whether there are true protective associations. 
 
 
5.3 LIMITATIONS AND STRENGTH  
 
As COPD patients experience symptoms differently they might be diagnosed in different 
stages of the disease. In addition patients might experience differences in disease 
progression. In a sensitivity analysis, where we stratified COPD patients according to therapy 
into mild, moderate and severe cases, we tried to account for the influence of disease 
severity. We used the therapy as a proxy for severity classification as there is only limited 
information on FEV1 values available. Although this leaves room for misclassification we feel 
that this method is a useful indicator in the absence of more specific measures, as treatment 
guidelines are oriented on FEV1 values. Soriano et al.(114) who validated a classification 
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scheme based on treatment found good correlation between FEV1 and treatment 
classification. 
As smoking is the most important risk factor for COPD it would be desirable to have complete 
smoking information for the analysis. There is the potential that COPD patients are more 
likely to be asked about their smoking status than controls and thus there might be some 
selective misclassification of smoking status. In the analysis this may have led to some 
dilution of potential COPD risk estimates towards 0. Additionally, it has been shown that 
smoking intensity might influence the risk of developing lung cancer or cardiovascular 
diseases, a factor we cannot account for in our analysis.  
In spite of these (small) limitations database research is in general a powerful tool to support 
pharmacovigilance. It is able to depict a picture of the real world, shows the effectiveness 
rather than the efficacy of drugs at affordable costs. Database research is much less affected 
by selection bias, which is a huge problem in clinical trials, which are often not conducted in 
the patients finally taking the drugs. The population of the GPRD is representative of the 
general UK population. (107) Database research does not replace clinical trials but adds 
important information to the safety profile of drugs and provides information on the clinical 
presentation of the underlying diseases. This research can even be conducted when clinical 
trials are considered unethical or are impossible to do. Compared to other epidemiological 
studies database research is less affected by selection and recall bias, as all information are 
entered at the time they are identified. 
 
  
 
 
 
 
 
CONCLUSION & OUTLOOK 
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6.1  CONCLUSION 
 
Evidence based medicine requires that decisions about the management of an individual 
case are based on “conscientious, explicit, and judicious use of current best evidence” and 
“individual clinical expertise.(235) This thesis provided further evidence that sometimes the 
important information is hidden in details and that best evidence can only be provided by 
specific guidance. COPD is no risk factor for stroke in men but it increases the risk in women. 
The following list summarises the most important findings of this thesis. Some of them 
confirm older findings from the literature, others rather present a hypothesis all of them apply 
to a situation in the GPRD between 1995 and 2005. Research in other settings, other 
countries and at other times will have to confirm or disprove these associations. 
 
 Patients with COPD have more co-morbidities and a higher mortality than COPD-
free patients. 
 
 Diabetes is underrepresented in men at the time of the first COPD diagnosis. This 
observation is at least in part contributed to higher proportion of ex-smokers 
among diabetic patients. Whether there is an association between sulfonylurea 
and the subsequent risk of COPD needs further investigation.  
 
 Patients with COPD have in general a higher risk of depression, lung cancer, 
pulmonary embolism and myocardial infarction. 
 
 Gender differences were observed for the risk of cancer (urinary cancer and lung 
cancer), myocardial infarction, stroke, depression, peptic ulcer, survival and 
respiratory drug utilization. 
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 Severity of COPD seemed to increase the risk of depression, myocardial 
infarction, pulmonary embolism and lung cancer. 
 
 The proposition that patients using long-acting beta agonists have a decreased 
risk of peptic ulcer needs further investigation. 
 
 Smoking is a strong risk factor, therefore smoking stratified analysis are 
important. 
 
 
6.2  OUTLOOK 
 
6.2.1  COPD PROJECT 
The answer yes there are gender differences in the natural history of COPD opens another 
whole array of new questions. This thesis suggested that patients with diabetes are 
underrepresented in patients at the time of their COPD diagnosis mainly in male patients. To 
further investigate this association one could follow diabetes patients from their diagnosis 
until they develop COPD or loss of follow-up. It is important that this study has detailed 
information on smoking history and intensity. MI and stroke showed gender different 
incidences in men and women with COPD. Further research is needed to identify whether 
this is due to a different exposure to known risk factors in this case it might be smoking, a 
higher susceptibility of women to the effects of COPD or an artefact of the study design used. 
There was no difference in the risk of arrhythmia. As women have been shown to be 
particularly at risk of Q-T prolongation it would be interesting to investigate the association 
stratified by arrhythmia type and see whether there are any differences. Depression 
negatively influenced survival in men with COPD but not women. An open question is 
whether this difference arises from different COPD staging in men and women with men 
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being more advanced in COPD than women and thus more likely to die. A study adequately 
addressing disease severity at the time of the depression diagnosis and then following 
patients until death or loss of follow-up might contribute new insights. A clinical study with 
direct patient contact might be more suitable than database research or validated markers of 
disease severity have to be identified.  
Women still have a higher life expectancy than men and catch up with smoking behaviours; 
therefore it is likely that the future typical COPD patient will be women even if women are not 
more susceptible to smoking than men. Gender difference in susceptibility to smoking is one 
of the unanswered questions when dealing with COPD but also other tobacco-associated 
diseases. Future research is needed adequately addressing differences in lung biology and 
exposure to environmental tobacco smoke. An important problem is that women smoke for 
different reasons than men and they are less likely to quit. (236) 
 
6.2.2.  GENDER 
Natural history of disease studies are important to identify and quantify gender differences. 
They have to sensitize researchers, health care providers and regulators and last but not 
least the public. However, they usually cannot answer the question why there are 
differences. The identification of a difference is only the first step in a chain of events which 
will hopefully lead to the identification of the underlying mechanism and finally to effective 
treatment or even prevention strategies.  
 
In women a further level of complexity when studying disease associations is introduced by 
changing hormonal status. Menopause marks a turning point after which the risk of many 
diseases increases and becomes similar to risks seen in men, an example is hypertension. 
In addition women on HRT might experience different risks for diseases than women not 
taking hormones (237) and to further complicate this HRTs are not alike.(238) The results of 
the „WHI“-trial (Women’s Health Initiative) have intensified the debate about the safety of 
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HRT preparations and thus also started intense research in this area so that in the future we 
might gain more information on this topic. Much less is known on women using oral 
contraceptives (OC) except maybe for their risk of venous thromboembolism.(239) Both 
HRTs and OCs might interact with other drugs. Pregnancy puts women requiring drugs at an 
immense psychological burden, they want the best for their babies but not much is known 
about drug effects and the comparison between effects of the disease itself and drug effects. 
Pregnant women are excluded from official clinical trials due to worries about teratogenic 
effects to the baby. Nevertheless, about two thirds of women delivering a baby have taken at 
least one prescription medication during their pregnancy. Thus pregnant women take part in 
uncontrolled and unmonitored experiments – one by one and most of their data were never 
assessed. There are now efforts to close this knowledge gap. The FDA and collaborators 
launched a program called the ‘Medical Exposure in Pregnancy Risk Evaluation Program’ to 
fund research on effects of prescription medications used during pregnancy. Therefore 
health care information from mothers and babies born between 2001-2007 will be linked and 
analysed providing information on about 1 million births.(240) There have been efforts to use 
the GPRD for investigating the effects of medication used during pregnancy, (241) however, 
these analyses are complicated because records of mothers and their children were not 
routinely linked.  
There is even less information on paternal drug exposure and pregnancy outcomes, although 
many fathers used drugs around the time of conception (242) and teratology information 
services are addressed by concerned future parents.(243, 244) Linking not only mothers with 
their children but also fathers in administrative database would enable us top learn more 
about the effects of paternal drug exposure on pregnancy outcomes. In case paternal drug 
exposure poses a risk this should also be considered in clinical trials by ensuring that men 
and women both take effective measures to prevent a pregnancy while they are participating 
in a clinical trial. 
Although this thesis mainly focussed on differences it is as important to identify equalities 
between gender, even if at first glance the assumption is that there is a difference. It is 
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always important to question an observation, same numbers might still present different 
underlying mechanism and different numbers might be due to diagnostic bias. Equalities 
have to be identified to avoid double standards and ensure that men and women receive the 
same therapy when they need it. Research on differences but also equalities between men 
and women is important to offer best care to the patient. Integration into medical guidelines 
and of course daily practice has to follow.  
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